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Insulin and muscle contractions mediate translocation of glucose 
transporter 4 (GLUT4) to the plasma membrane for glucose uptake in 
skeletal muscles. Tropomodulin3 (Tmod3), an actin-capping protein 
that blocks the elongation and de-polymerization of actin filaments at 
the pointed end, is an Akt2 substrate  and plays a vital role in GLUT4 
fusion with the plasma membrane and glucose uptake under insulin-
stimulated condition. It is well understood that insulin promotes GLUT4 
translocation and glucose uptake in muscles and adipocytes by 
PI3K/Akt signaling pathway. Although it is believed that AMPK (5’ 
adenosine monophosphate-activated protein kinase) signaling 
regulates GLUT4 translocation during muscle contraction, the exact 
regulating mechanisms are not clearly elucidated. Bioinformatics and 
biochemical analysis identified Ser25 residue of Tmod3 as a potential 
site of phosphorylation. Ser25 phosphorylation was required for 
activated-AMPK-induced GLUT4 translocation and glucose uptake in 
L6 myoblasts, providing new mechanistic insights in the regulation of 
glucose homeostasis. Furthermore, Tmod3 played a key role in AMPK-
induced actin re-modeling and in activated-AMPK-stimulated GLUT4 
fusion with the plasma membrane and glucose uptake. Tmod3 is 
identified as a key downstream effector of AMPK in the regulation of 
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CHAPTER I  
INTRODUCTION 
 
The fundamental biological questions addressed in this thesis    
primarily concern GLUT4 trafficking in response to activated-AMPK 
stimulation that promotes glucose transport in muscle cells. Indeed, a 
comprehensive understanding of the molecular and cellular processes 
that control GLUT4 trafficking and glucose uptake is vital to understand 
regulation of blood glucose homeostasis and to identify potential drug 
targets for the treatment of metabolic disorders, such as diabetes, 
where the regulation of blood glucose homeostasis is compromised.  
1.1 Blood Glucose homeostasis  
Glucose is the fundamental fuel source for all eukaryotic cells. Glucose 
molecules are metabolized within the cells to produce energy-rich 
molecules, adenosine triphosphate (ATP), which fuel numerous cellular 
processes. Glucose molecules are delivered to cells throughout the 
body via the circulatory system. In order to ensure a constant glucose 
supply to the cells, it is crucial to maintain relatively constant blood 
glucose levels. Blood glucose homeostasis is mainly achieved through 
the antagonistic actions of two pancreatic hormones, insulin and 
glucagon. These hormones orchestrate the balance between the 
glucose uptake, catabolism, storage, hepatic glucose production and 
release. Increase in the blood glucose level triggers the Insulin 
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secreted from pancreatic β-cells resulting in glucose uptake and 
storage in insulin-sensitive tissues, such as the brain, liver, adipose 
tissue and skeletal muscle. Skeletal muscle is the major site of glucose 
disposal as it accounts for up to 90% of glucose uptake [1]. In the 
skeletal muscle, glucose molecules are catabolized to yield ATP and, 
excess glucose molecules are stored as glycogen in the skeletal 
muscles and liver, whilst as triglycerides in the adipose tissues. In 
response to insulin secretion, reduction in hepatic glucose production 
and release is achieved by the inhibition of hepatic de novo synthesis 
of glucose and glycogen catabolism, eventually leading to reduction in 
blood glucose levels. In case of hypoglycemia, pancreatic α-cells 
release glucagon to stimulate hepatic glucose production and release 
in order counter the drop in blood glucose levels.  
1.2 Diabetes  
Diabetes is a metabolic disorder in which blood glucose level is higher 
than the normal physiological range. There are two types of diabetes 
based on their etiologies, Type 1 and Type 2. Type 1 diabetes is 
characterized by a failure to produce insulin in response to increased 
blood glucose levels, which is caused by an auto-immune destruction 
of pancreatic β-cells. Type 2 diabetes is characterized by 
hyperglycemia due to insulin resistance in insulin sensitive peripheral 
tissues and impaired pancreatic β-cell function and insulin secretion as 
a consequence of prolonged hyperglycemia [2]. The most common 
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treatment for type 1 diabetes is injection of exogenous insulin whereas 
in case of type 2 diabetes, physical exercise, strict dietary control, and 
anti-diabetic drugs like metformin are used [3]. According to 
International Diabetes Federation (IDF) worldwide data of 2015, around 
415 million adults have type 2 diabetes and it is reported that the 
number of cases will reach 642 million by the year 2040. The major 
health complications of diabetes include increased rate of stroke, 
coronary heart failure, diabetic retinopathy and diabetic nephropathy [4, 
5]. Hence, investigations of potential drug targets and treatments for 
type 2 diabetes hold great importance in the area of biomedical 
research.   
1.3 Glucose Transporters (GLUTs) 
The transport of glucose across the plasma membrane of the cells for 
metabolism occurs through the glucose transporter (GLUT) family of 
ATP-independent facilitative transporters. These transporters act as a 
shuttle to mediate the bi-directional transport of glucose molecules 
across the lipid bilayer of plasma membrane and this step is 
considered as the rate limiting step in glucose transport which has 
made it a focal point of diabetes research. 
There are 14 members of the GLUT family which are further 
divided into three subclasses. GLUTs 1-4 and 14 belong to class I 
GLUTs. The fructose transporters GLUT5, 7, 9 and 11 belong to class 
II and GLUTs 6, 8, 10, 12 and HMIT belong to class III. Each GLUT 
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has specific role depending upon their localization and trafficking 
itineraries.  
Structurally, GLUTs are predicted to have 12 transmembrane 
helices with cytosolic N- and C-termini [6] containing unique sequences 
that direct their characteristic membrane trafficking capability. Class I 
and II GLUTs have two large loop regions; 1) the first loop is 
extracellular with N-linked glycosylation site and sits between the first 
and second transmembrane domains and 2) the second loop is highly 
hydrophilic intracellular that sits between transmembrane helices 6 and 
7. Class III GLUTs have two extracellular loops; 1) a small loop without 
glycosylation site between the first and second transmembrane helices 
and 2) a larger loop with N-linked glycosylation site between 





















Figure 1.3 Schematic diagram of Class I GLUTs. GLUTs are 
predicted to contain twelve membrane spanning domains. 

















1.4 Glucose Transporter4 (GLUT4) as a key determinant of blood 
glucose homeostasis 
Tissues with a very high energy demand such as the brain, which is 
responsible for up to 80% of whole-body glucose consumption in 
resting conditions, express GLUTs such as GLUT1, 2 and 3 which are 
constitutively localized to the cell surface. GLUT4 (gene name: 
SLC2A4) is the most specialized GLUT in terms of subcellular 
localization. GLUT4 is predominantly expressed in the insulin-sensitive 
tissues like muscle and adipose tissue. It has also been reported to be 
expressed in some glucose sensing and metabolic regulating regions 
of the brain like the hypothalamus as well [8]. GLUT4 storage vesicles 
(GSVs) translocate from an intracellular location to the plasma 
membrane in response to insulin in muscle fibres and adipose cells in 
order to mediate the insulin-stimulated glucose uptake. A quick survey 
of the literature suggest that there are no any known polymorphisms 
within the GLUT4 gene that would be associated with the impaired 
blood glucose homeostasis such as in case of type 2 diabetes. 
A crucial role of GLUT4 in whole body blood glucose 
homeostasis has been strongly supported by a number of evidences 
from animal studies where GLUT4 expression is ablated or enhanced 
in adipose tissue or muscle or both. Previous studies have shown that 
in GLUT4-/- mice functional GLUT4 protein is linked to cardiac, skeletal 
muscle and adipose tissue abnormalities but not to diabetes [9, 10]. 
However, GLUT4+/- mice with decreased GLUT4 protein and mice with 
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tissue specific conditional depletion of GLUT4 have been reported to 
exhibit insulin resistance in adipose tissue [11, 12] and muscle [13, 14] 
and propensity to diabetes.  
Likewise, insulin-stimulated glucose uptake is significantly 
reduced in muscle-specific insulin receptor knockout (MIRKO) [15] or 
adipose-specific insulin receptor knockout (FIRKO) [16] mice. 
Conversely, transgenic mice over-expressing GLUT4 in adipose tissue 
or muscle exhibit improved insulin sensitivity and glucose tolerance 
[17-19]. In patients with type 2 diabetes, mRNA and protein levels of 
GLUT4 are exclusively down-regulated in adipose tissue but not in 
skeletal muscle [20-22]. Thus, GLUT4 has been shown to play 
indispensable role in maintaining normal blood glucose homeostasis. 
1.5 Regulation of Endogenous GLUT4 expression 
The profound effects of GLUT4 deficiency or over-expression on whole 
body blood glucose homeostasis in mouse models heighten the 
significance of changes in the endogenous GLUT4 expression, 
particularly the up-regulation in skeletal muscle in response to exercise 
and down-regulation in adipose tissue in obesity.  
Tissue specific expression of GLUT4 gene in skeletal muscle, 
adipose tissue and cardiac muscle is conferred within its 2.4 kb DNA 
segment at 5’ region [23]. The region between -522 and 420, with 
myocyte enhancer factor (MEF)2 binding domain at -466 to -457, is 
important for skeletal muscle specific GLUT4 expression[24, 25] and 
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for increased GLUT4 expression during muscle regeneration in 
transgenic mice [26].  
It has been reported that near this 82-bp region MyoD and 
thyroid hormone receptor (TRalpha1) form a complex with MEF2 to 
regulate GLUT4 expression [27]. In another region between -742 and -
712, a transcriptional activator, GLUT4 enhancer factor (GEF) interacts 
with MEF2A to regulate the GLUT4 gene promoter [28].However, the 
regulation of GLUT4 translation or degradation at protein or mRNA 
level is still unclear. 
1.6 Intracellular Localization of GLUT4 
The intracellular localization of GLUT4 is a dynamic and complex 
transport itinerary. Given that under the influence of physiological 
stimuli, the subcellular localization of GLUT4 modifies to promote the 
glucose uptake, it is crucial to know the relationship between the 
signaling pathways and the intracellular sequestration of GLUT4 under 
basal conditions to shed light on how the physiological stimuli, such as 
insulin and AMPK activators, enhance the cell surface levels of GLUT4. 
Biogenesis of GLUT4 occurs through multiple cell organelles. 
GLUT4 is found in many cell organelles, including plasma membrane, 
early/sorting endosomes, recycling endosomes, tubule-vesicular 
network connected to endosomal-trans-Golgi network (TGN) system 




1.7 Formation of GSVs  
Previous studies have shown that a proportion of GLUT4 is present in 
the TGN of muscle and adipose cells [30-32]. In presence of protein 
synthesis inhibitors, GLUT4 is not blocked from entering into GSVs 
from TGN [33]. In addition, the studies on GLUT4 internalization from 
the cell surface have identified that GLUT4 translocates through 
endosomes to a peri-nuclear compartment which is distinct from 
recycling endosomes [34]. Taken together, these data support a role of 
TGN in the sorting of recycling GLUT4 into the GSV compartment. 
Therefore, the accumulation of GLUT4 in the GSV compartment is 
likely to occur via endosomes and TGN and more directly from the 
TGN.  
Several proteins have been proposed to be involved in GLUT4 
sorting into the GSVs. Adaptor protein-1 (AP-1), clathrin-coated 
vesicles translocating from the TGN, have been reported to be co-
localized to GLUT4 [35, 36] suggesting that GLUT4 recruitment to 
these vesicles permits sorting of GLUT4 from other proteins during 
translocation from TGN to the storage compartment. Moreover, Golgi 
localised γ-adaptin ear homology domain, Arf (ADP ribosylation factor) 
binding proteins (GGAs) have been reported to interact with cargo 
containing di-leucine (LL) motifs which are present in both GLUT4 and 
the GSV localized protein, insulin-responsive aminopeptidase (IRAP) 
[37]. Sortillin binds to the lumenal domains of GSV proteins such as 
GLUT4 and IRAP and has been proposed to be involved in further 
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sorting step downstream of GGAs in selecting proteins to traffic to 
GSVs [38]. Eps15 Homology (EH) domain containing proteins which 
are involved in membrane sorting and trafficking events in the cell, 
particularly the recycling of receptors to the plasma membrane via the 
recycling endosome [39], have also been proposed to play a role in the 
formation of GSVs. EHD1 has been reported to interact with the Rab11 
effector Rab11-FIP2 [40] which is thought to be important in sorting 
GLUT4 from endosomes and into the GSV [41]. As GLUT4 and other 
GSV resident proteins are selectively sorted into GSVs, they must 
contain specific signals to mediate the trafficking.  
GLUT4 contains N- and C-terminal sorting motifs (FQQI and LL) 
[42-44] which resemble adaptor protein (AP) binding motifs indicating 
that GLUT4 and AP- interacts and promotes GLUT4 internalization. 
However, these N- and C-terminal sorting motifs are required for 
GLUT4 trafficking from the recycling endosomes and into the GSV 
compartment. IRAP contain a C-terminal TELEY motif, which has also 
been implicated in GLUT4 trafficking to the GSV compartment [43, 44]. 
These FQQI and TELEY motifs are involved in the sorting of GLUT4 
out of recycling endosomes to the GSV compartment [43]. The exact 
role of these motifs and the predominant point at which they act in 















Figure 1.7 GLUT4 entry into the GSV compartment. GLUT4 is 
trafficked into the GSV compartment through two routes. Newly 
synthesized GLUT4 enters via the endoplasmic reticulum and 
Golgi complex (Biosynthetic Pathway). Recycling GLUT4 re-enters 
the GSV compartment from the endosomal compartment, via the 























1.8 GLUT4 Translocation and glucose uptake 
Both exercise and insulin acutely stimulate GLUT4 recruitment to the 
plasma membrane of the skeletal muscle and adipose cells 
independent of transcription and translation. Approximately 90% of 
insulin-stimulated blood glucose uptake occurs in skeletal muscle [45]. 
Adipose tissue accounts for only about 10% of insulin-stimulated blood 
glucose uptake, but it is important for regulating whole-body energy 
homeostasis, as adipocytes serve as a cellular 'rheostat' to sense the 
energy status, and regulates metabolism by secreting numerous 
hormones, such as cytokines and chemokines in brain, muscle and 
liver [12, 14]. Nevertheless, exercise and insulin initiate distinct 
signaling mechanisms to promote GLUT4 translocation and glucose 
uptake.  
1.8.1 Insulin Signaling Pathway 
In canonical insulin signaling pathway, insulin secreted from pancreatic 
β-cells binds to its insulin receptor tyrosine kinase (IP) resulting in its 
phosphorylation.  The activation of IR phosphorylates and recruits 
different substrate adaptors such as insulin receptor substrate (IRS) 
proteins. Phosphorylated IRS proteins in turn activate 
phosphoinositide-3-kinase (PI-3-K), which eventually converts 
phosphatidylinositol (4, 5)-bisphosphate (PIP2) to phosphatidylinositol 
(3, 4, 5)-triphosphate (PIP3). PIP3 recruits protein kinase B (Akt) to the 
plasma membrane, thereby leading to Akt activation through the 
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actions of the intermediate protein kinases, Rictor/mTOR [46] and 
PDK1 [47]. Akt2 rather than Akt1 or Akt3 isoforms controls GLUT4 
vesicle trafficking in muscles and adipocytes and mediate insulin-
signaling to control hepatic glucose output [48-50]. Recently, activated-
Akt2 has been reported to phosphorylate actin-capping protein, 
Tropomodulin3. Phosphorylated Tmod3 interacts with its cognate 
tropomyosin partner, Tm5NM1 to promote both membrane and cortical 
actin filament remodeling leading to insulin-stimulated GLUT4 fusion 

































Figure 1.8.1 Schematic diagram of insulin-stimulated GLUT4 
fusion with plasma membrane and glucose uptake. Activation of 
the insulin receptor results in the recruitment of PI-3-K to the 
plasma membrane through an interaction with phosphorylated 
IRS1/2. PI-3-K converts PI(4,5)P-2 to PI(3,4,5)P-3 at the inner leaflet 
of the plasma membrane. PI(3,4,5)P-3 recruits PDK-1, PKB/Akt and 
PKC to the plasma membrane. PKB/Akt and PKC are activated by 
phosphorylation and mediate insulin’s effects on cellular 











































1.8.2 Insulin-Independent Signaling Pathway 
In addition to insulin stimulation, contraction and exercise also enhance 
glucose transport in skeletal muscle through GLUT4 redistribution to 
the plasma membrane. There are many studies which have reported 
that contraction operates through a distinct but separate signaling 
cascade other than insulin-signaling in skeletal muscle. Additive effect 
of Insulin stimulation and contraction in enhancing glucose transport 
has also been reported [52].  
Despite of some contradictory reports, in skeletal muscle, 
contraction-mediated glucose uptake is generally insensitive to the PI-
3-K inhibitor wortmannin [52-54] which is in contrast to the report that 
the contraction-stimulated glucose uptake and GLUT4 vesicle 
translocation in cardiomyocytes is sensitive to wortmannin [55]. 
Considering the difference in sensitivity to PI-3-K inhibitor, subtle 
differences in how contraction signals to promote glucose uptake 
between muscle sub- and fibre-types may be predicted. Previous 
studies have reported that the exercise, contraction, hypoxia and direct 
AMPK-activation-mediated mechanisms, leading to glucose uptake, 
remain intact in insulin-resistant individuals [56-60]. Further 
characterization of these insulin-independent signaling pathways may 






1.8.2.1 AMP-activated protein kinase (AMPK) 
5'-AMP-activated protein kinase or 5'-adenosine monophosphate-
activated protein kinase (AMPK) plays a key role as a master regulator 
of cellular energy homeostasis. It is activated in response to a fall in the 
ATP: AMP ratio, the glycogen content of the cell or as a result of 
hormonal signaling due to stresses, such as low glucose, hypoxia, 
ischemia, and heat shock [61-64]. AMPK activation switches 
metabolism from an anabolic to a catabolic states regulating metabolic 
enzymes and gene expression.  
AMPK is a heterotrimeric protein consisting of a catalytic α-
subunit (α1 or α2) and two regulatory β- and γ-subunits (β1 or β2 and 
γ1, γ2 or γ3). Twelve different AMPK complexes have been identified 
so far. The upstream kinases, such as LKB-1 [65, 66], 
Ca2+/calmodulin-dependent protein kinase kinase β (CaMKKβ) [67-69] 
and transforming growth factor-β-activated kinase (Tak1) [70], lead to 
phosphorylation of threonine 172 residue in the T-loop region of α-
subunit and enhance AMPK kinase activity over 100-folds [71]. 
Additional phosphorylation and auto-phosphorylation sites in the α- and 
β-subunits have been reported to further regulate AMPK activity and 
localization [72, 73].  
AMPK kinase activity is also regulated by AMP binding at γ-
subunit via ‘Bateman domains’. AMP binding allosterically activates 
AMPK [71] resulting in indirect inhibition of threonine 172 residue de-
phosphorylation [74]. These two-pronged effects make AMPK 
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extremely sensitive to drop in the cellular ATP: AMP ratio. In addition, 
AMPK activity is also regulated by glycogen binding at β-subunit which 
results in inhibition of AMPK activity during state of high glycogen level. 
AMPK activation by the AMP analogue 5-aminoimidazole-4-
carboxamide ribonucleoside (AICAR) or by hypoxia in skeletal muscles 
has been correlated with enhanced glucose uptake. Muscle contraction 
and AICAR- or hypoxia-stimulation do not additively enhance glucose 
transport indicating the role of AMPK in contraction signaling to glucose 
uptake [58, 75]. AMPK activators, such as AICAR, adiponectin, IL-6 
and the mitochondrial inhibitor DNP have been reported to promote 
GLUT4 trafficking to the cell surface [76]. Besides these activators, a 
small molecule AMPK activator A-769662 has been reported to 
enhance glucose uptake in L6 myocytes [77].  
As AMPK plays a major role in regulating energy homeostasis, it 
is a prime therapeutic drug target for treatment of metabolic syndromes 
such as type 2 diabetes [78]. AMPK activator AICAR has been shown 
to reverse metabolic abnormalities in obese and insulin-resistant 
mouse models [79-81]. The most commonly prescribed anti-diabetic 
drug metformin has been reported to reduce circulating glucose levels 
in insulin-resistant patients through activation of AMPK by inhibition of 
gluconeogensis in the liver [82, 83]. This additional activation of AMPK 
at peripheral sites may provide further beneficial effects in reducing the 















Figure 1.8.2 Schematic diagram of AMPK-stimulated GLUT4 
trafficking and glucose uptake. A change in the cellular energy-
status during exercise or contraction lowers the ATP:AMP ratio 
and activates AMPK. AMPK activation leads to enhanced GLUT4 
translocation and glucose uptake by the mechanism which is still 
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1.9 Potential convergence of signaling pathways leading to 
GLUT4 translocation and glucose uptake  
The molecules at which exercise/contraction- and insulin-stimulated 
signaling pathways converge may have pathophysiological relevance 
so as to bypass the point of failure in insulin-mediated GLUT4 
translocation such as in case of insulin-resistant patients. Recently, 
Rab-GAPs TBC1D4/AS160 and TBC1D have been focused to bridge 
exercise/contraction- and insulin-stimulated signaling pathways.  
TBC1D4/AS160 is phosphorylated in response to contraction, 
AICAR and insulin stimulation [84-89]. An increase in immuno-reactivity 
of TBC1D4/AS160 and TBC1D1 with the PAS antibody has been 
elucidated in response to contraction stimulation in an AMPK-
dependent [90, 91] and PKB/Akt phosphorylation-independent manner. 
Moreover, in rat epitrochlearis muscle inhibition of AMPK and PKB/Akt 
by Compound C or wortmannin respectively, has shown differential 
regulation of phosphorylation of TBC1D1 and TBC1D4/AS160 in 
response to contraction as measured by PAS antibody reactivity [91]. 
Contraction-stimulation TBC1D1 PAS-reactivity was completely 
inhibited with inhibition of AMPK. Likewise, contraction-mediated 
TBC1D4/AS160 PAS-reactivity was inhibited under wortmannin 
treatment indicating that the phosphorylation is mediated by PKB/Akt 
but not AMPK. These data suggest that, although TBC1D1 and 
TBC1D4/AS160 are phosphorylated following both contraction-and 
insulin stimulation in the muscle, only TBC1D1 is a potential candidate 
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to be considered as a site of convergence for distinct AMPK and 
PKB/Akt signaling pathways as TBC1D1 is the major Rab-GAP 
expressed in this muscle type. In addition, Ca2+/calmodulin-mediated 
effect on TBC1D4/AS160, a correlation between the kinetics of CaMKII 
activation and TBC1D1 and TBC1D4/AS160 phosphorylation in 
response to contraction has been reported [92] but the role of  CaMKII 
in direct phosphorylation of these Rab-GAP proteins is still not clear.  
Over-expression of kinase inactive form of the AMPK α2 subunit 
in mice has revealed that contraction and AICAR induce 
phosphorylation of serine 237 and threonine 596 in TBC1D1 and 
promote 14-3-3 binding to TBC1D1 in an AMPK-dependent manner 
[93]. In addition, under insulin stimulation phosphorylation of serine 237 
was abolished which is in support of data obtained in L6 cells [94]. 
Interestingly, insulin-stimulated phosphorylation of threonine 596 is 
also abolished upon overexpressing catalytically inactive AMPK in 
mice. All data taken together suggest that TBC1D1 is primarily 
regulated by AMPK and in order to prime TBC1D1 for insulin-
stimulated phosphorylation of threonine 596, AMPK requires 
phosphorylation sites other than threonine 596. Moreover, over-
expression of TBC1D4/AS160 has been shown to inhibit AMPK-
stimulated GLUT4 translocation by the TBC1D4/AS160-4P indicating 
that the over-expression may have dominant negative effect on both 
TBC1D1 and TBC1D4/AS160. 
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In AMPKγ3 knockout mice, TBC1D4/AS160 / TBC1D1-
independent mechanism has been shown to contribute to glucose 
transport in skeletal muscle [95]. In support to this, differentially 
affected GLUT4 trafficking kinetics under insulin and AMPK stimulation 
in muscle has been observed [55, 96, 97]. Given that AMPK 
phosphorylates AS160/TBC1D4 and TBC1D1, AICAR would therefore 
be expected to modulate GLUT4 exocytosis. But insulin stimulation 
enhanced GLUT4 exocytosis and AMPK-activation inhibited GLUT4 
internalization have been reported in human and rat skeletal muscle 
[96].  It would be of great interest to identify the changes in contraction-
induced GLUT4 trafficking and investigate how the phosphorylation of 
TBC1D1 and TBC1D4/AS160 affects GLUT4 trafficking. 
Under insulin stimulation, atypical PKC-mediated 
phosphorylation of serine 588 in TBC1D4/AS160 in 3T3L1 adipocytes 
has been reported [98], suggesting that serine 588 may also be 
phosphorylated in response to contraction-stimulation. Besides these, 
PKB/Akt substrate PIKfyve has been observed to be phosphorylated in 
CHO-T cells under hyperosmotic stress in PI-3-K-independent manner 
[99]. Since hyperosmotic stress has been reported to promote GLUT4 
translocation in both L6 muscle cells and 3T3-L1 adipocytes, PIKfyve 
may act as convergence point of insulin and AMPK signaling pathways 




Recently, Tmod3, an acting binding protein, has been identified 
as Akt2 substrate and phosphorylation of Tmod3 at serine 71 
potentiates insulin-stimulated GLUT4 fusion with the plasma 
membrane and glucose uptake in adipocytes. In this thesis, serine 25 
but not serine 71 has been identified to be phosphorylated under 
AMPK activation in L6 myoblasts and promotes GLUT4 trafficking and 
glucose uptake, suggesting that Tmod3 is a potential candidate site of 
convergence of AMPK and insulin signaling pathways. 
 1.10 SNARE regulation during GSV fusion 
Following the translocation to the plasma membrane, GSVs have to 
dock and fuse with the plasma membrane in order to facilitate the 
glucose transport into the cell. The process of GSVs fusion with the 
plasma membrane is evolutionarily conserved which requires N-
ethylmaleimide sensitive factor (NSF), soluble NSF attachment 
proteins (SNAPs), SNAP receptors (SNARE) and small Rab GTPases. 
A ternary complex of the vesicle SNARE on GSVs, VAMP2 [100], and 
the plasma membrane (target membrane) SNAP23 [101] and syntaxin-
4 [102] form SNARE complex which is considered to bring the vesicle 
and target membrane into close proximity, thereby facilitating fusion.  
Total internal reflection fluorescence microscope (TIRFM) 
studies have indicated that the rate of GSV fusion increases under 
insulin stimulation, most probably in Akt-dependent manner [103, 104]. 
In basal cells, Munc-18c, a member of Sec1/Munc18 protein family, 
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interacts with syntaxin-4 and prevents syntaxin-4 association with 
VAMP2 and SNAP23. Munc-18c is thought to switch from negative 
regulators of SNARE assembly to the fusogenic machinery component 
during the vesicle fusion process, which may occur due to change in 
the mode of binding to syntaxins [104]. Insulin-mediated Munc18-c 
regulation is not clearly understood. Some studies have suggested that 
the mode of Munc18-c binding to syntaxin-4 is altered by insulin 
resulting in its fusogenic function [104, 105]. Munc-18c and syntaxin-4 
interaction is disrupted by Insulin stimulation via the phosphorylation of 
Munc-18c at tyrosine 219 [106]. Another study has shown that 
phosphorylation of Munc-18c at tyrosine 521 by the insulin receptor 
tyrosine kinase abrogates monomeric syntaxin-4 and VAMP2 binding, 
suggesting that this event may play a crucial role in delivery of GLUT4 
to the plasma membrane in insulin-stimulated SNARE-mediated 
manner [107]. 
In addition to the insulin-sensitive phosphorylation of Munc-18c, 
PKB/Akt and PKCζ-mediated phosphorylation of VAMP2 has been 
reported but the role of the phosphorylation is yet to be investigated 
[108, 109]. Inhibition of VAMP2 function through cleavage by botulinum 
toxin has been shown to inhibit GLUT4 appearance at the cell surface 
[110]. Only knocking out all three v-SNARE isoforms, VAMP2, 3 and 8, 
completely inhibits insulin-stimulated GLUT4 translocation and rescues 
this phenotype upon re-expression of either of these isoforms [111], 
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indicating the plasticity in the requirement for v-SNAREs in GLUT4-
vesicle fusion with the plasma membrane under insulin stimulation.  
In pancreatic β-cells, phosphorylation of Munc-18c at tyrosine 
219 under glucose stimulation increases its binding to double C2-like 
domain-containing protein-β (DOC2β) inhibiting syntaxin-4 binding 
[106]. DOC2β has been implicated as a positive regulator of vesicle 
fusion in adipocytes [112]. Other proteins include negative regulators of 
SNARE complex assembly through syntaxin-4 binding, such as, 
Tomosyn, which is involved in neurotransmitter release [113] and 
synip, which is specifically phosphorylated by PKBβ/Akt2 under insulin 
stimulation [114]. The majority of these studies have been carried out 
in adipocytes, however the fusion machinery and its regulation is 
thought to be analogous in muscle tissues.  
CD138, a novel Akt substrate, positively regulates GLUT4 
insertion into the plasma membrane in adipocytes. The phospho-
defective mutant, S197A, has been reported to block GSV fusion but 
not the vesicle accumulation at the plasma membrane [115].The C2-
domain of CD138 shares homology with synaptotagmin protein C2-
domain which is reported to promote vesicle fusion and induce 
membrane curvature by binding to lipids in calcium ion dependent 
manner [116]. 
The evidence for the mechanisms regulating the docking and 
fusion of GLUT4 vesicles to the cell surface during muscle contractions 
or AMPK activation is very limited. V-SNARE isoforms, VAMPs 2, 3, 5 
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and 7 are expressed in skeletal muscle but only VAMPs 2, 5 and 7 
have been identified to be involved in GLUT4 translocation to the cell 
surface in skeletal muscle [117].  Further work into the specific effects 
of AMPK stimulation at the plasma membrane in modulating GSV 
docking and fusion will be required to further understand the effects of 
AMPK stimulation. This will be aided by taking advantage of the in vitro 
fusion assay and through the TIRF microscopy and analysis programs. 
1.11 Role of Cortical Actin in GLUT4 exocytosis 
The actin cytoskeleton is a dynamic structure primarily important for 
compartmentalization of signaling molecules, cell organelles, cell 
mobility and cellular structural support [118, 119]. Most of non-muscle 
cells express cytoplasmic (non-sarcomeric) actin (CYA) β and γ 
isoforms to display insulin-mediated cortical actin remodeling [120, 
121]. Both CYA β and γ isoforms reorganize dynamically into filaments. 
In L6 myoblasts and other cell types, γ-CYA is localized to actin stress 
fibers of the cell body while β-CYA is more prone to cortical actin 
filament formation [122]. Cortical actin remodeling is a dynamic 
process involved in polymerizing globular actin (G-actin) to filamentous 
actin (F-actin) [123]. 
Microtubules provide a route by which GSVs can translocate to 
the cell surface. Disruption of the microtubule network results in a 
significant reduction in GLUT4 redistribution to the plasma membrane.  
Specifically, insulin has been reported to stimulate actin cytoskeleton 
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remodeling in adipose tissue [51] and skeletal muscle cells, which is 
important for GLUT4 translocation to the cell surface and glucose 
uptake [118, 119]. Insulin promotes lamellipodia membrane ruffles 
formation [124, 125] where insulin signaling molecules co-localize and 
GLUT4 vesicles are fused with the plasma membrane [118-120, 124]. 
Cytoskeleton disruption by Cytochalasin D and Latrunculin B inhibits 
activation of PI3K and Akt and also impairs GLUT4 vesicle fusion but 
not trafficking to the cell cortex [126].  
It has been reported that growth factor receptor tyrosine kinases 
signal to Rho-GTPases to induce actin remodeling [127] by recruiting 
downstream actin nucleation factors  and thereby enhance actin 
polymerization and regulation of de-polymerization of F-actin into 
monomers with proper actin dynamics [128]. The nucleation factor, 
Wiskott - Aldrich syndrome protein (WASp) has been reported to play 
important role in actin remodeling. WASp binds to Actin-related 
proteins complex, Arp2/3, resulting in the activation of the complex. 
The activated Arp2/3 directly binds to actin filaments to catalyze the 
formation of actin filament branches [129]. The N-WASp and Arp3 
subunit of Arp2/3 complex co-localizes with the polymerized F-actin in 
response to insulin stimulation [130]. Taken together, these results 
suggest that insulin-activated Rac1 acts through Arp2/3 complex to 
regulate actin remodeling. 
The process of de-polymerization is important to regenerate the 
pool of free monomeric actin for other rounds of actin assembly [131]. 
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Cofilin and actin-depolymerizing factor (ADF) are actin binding proteins 
that play a vital role in regulating actin filament dynamics and re-
organization by stimulating the severance and de-polymerization of 
actin filaments. Cofilin and ADF are phosphorylated and thereby 
inactivated through Rac1-dependent activation of LIM kinases and 
testicular protein kinases (TESKs). On contrary, the cofilin-specific 
phosphatase slingshot is activated with the actin polymerization and 
thereby de-phosphorylating (activating) cofilin [132]. Under insulin 
stimulation, the de-phosphorylation effect predominates suggesting 
that actin filament de-polymerization is an obligatory step in insulin-
induced actin remodeling [133].  
Several other signaling molecules have been implicated in 
insulin-stimulated actin remodeling. Atypical Protein Kinase C family 
(aPKCs) further regulates the insulin-induced actin remodeling. Insulin 
activates aPKCζ resulting in co-localization with remodeled actin near 
the plasma membrane [134]. However, the mechanism involved in 
aPKCζ-mediated Rho-GTPase-dependent actin remodeling is still 
unclear. Rho-GTPases, TC10 regulates the insulin-mediated acting 
remodeling in adipocytes. In contrast, Rac1 activation regulates the 
insulin-induced actin remodeling in L6 muscle cells [124, 135]. Another 
Rho family GTPase, Cdc42, has been reported to be activated 
following insulin stimulation to promote glucose uptake in 3T3-L1 
adipocytes [136].  
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Myo1c, a motor protein that mediates movement along actin 
filaments, has been reported be phosphorylated in response to insulin 
stimulation [137] and mediates both insulin-stimulated and contraction-
stimulated glucose uptake in mouse skeletal muscle [138]. The 
importance of understanding the exact role of the cytoskeleton and its 
regulators in insulin-regulated GLUT4 trafficking is further emphasized 
by the finding that cortical actin filaments are lost in insulin-resistant L6 
muscle cells [139]. Therefore, disruption of these filaments is more 
likely to contribute to the insulin-resistant phenotype.  Recently, Tmod3 
has been reported to interact with the tropomyosin, Tm5NM1, thereby 
regulating the cortical actin remodeling, which eventually facilitates 
GLUT4 fusion with the plasma membrane under insulin stimulation 
[51].  
To date, little is known regarding the cortical actin remodeling by 
insulin-independent signaling. Previously in human endothelial 
progenitor cells, adiponectin has been shown to induce migration 
activity through cytoskeleton remodeling which is regulated by 
PI3K/Cdc42/Rac1 pathway [140]. Moreover, adiponectin suppresses 
cell migration in human coronary artery endothelial cells through 
inhibition of actin stress fiber formation [141]. Globular adiponectin has 
been reported to induce LKB1/AMPK-dependent glucose uptake 
through actin cytoskeleton remodeling in skeletal muscle cells [142]. 
Although there are substantial evidences suggesting that activated-
AMPK mediates cortical actin remodeling which is important for GLUT4 
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vesicle translocation and glucose uptake, the molecular mechanism 
linking AMPK signaling and actin remodeling is yet to be elucidated. 
1.12 Tropomodulins (Tmods) 
It has been reported that Tmod3-Tm5NM1 interaction is required for 
GLUT4 fusion with the plasma membrane and glucose uptake under 
insulin stimulation in adipocytes [51]. Tropomodulins (Tmods) are actin 
capping proteins that prevent de-polymerization and elongation of actin 
filaments at slow-growing pointed ends [143, 144]. There are four 
isoforms of Tmod (Tmod1, Tmod2, Tmod3 and Tmod4) each of which 
is expressed in a tissue-specific manner. Tmod1 is primarily expressed 
in terminally differentiated, post-mitotic cells, such as lens fiber cells, 
neurons, RBCs and striated muscle, Tmod2 is expressed primarily in 
neurons, Tmod3 is ubiquitously expressed and Tmod4 is expressed in 
skeletal muscle in mammals [144] .  
 Erythrocytes from Tmod1-null mice develop abnormal sphero-
elliptocytic shape with increased osmotic fragility, reduced deformability 
and disrupted membrane skeleton, showing that Tmod1 is associated 
with the membrane integrity [145]. In addition, Tmod1-null skeletal 
muscle cells have been found to have swollen sarcoplasmic reticulum 
and misaligned myofibrils [146, 147]. In Tmod4-null mice, the length of 
thin filament is regulated by compensatory upregulation of Tmod1 
[148]. Deletion of Tmod3 by RNA interference in human microvascular 
epithelial cells (HMEC-1) leads to enhanced cell migration and 
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increase in free pointed and barbed ends in actin filaments [149]. 
Likewise, targeted deletion of Tmod3 leads to  embryonic lethality at 
E14.5-E18.5 with anemia due to impairment in erythroid terminal 
differentiation in fetal liver [150]. Recently, actin polymerization by 
Tmod3 has been reported to regulate platelet biogenesis and 
megakaryocyte actin-organization [151]. Moreover, Tmod3 plays a 
crucial role in oocyte maturation, presumably by inhibiting actin filament 
de-polymerization [152]. It has been shown that Tmod4 promotes 
adipogenesis by up-regulating the expression of adipogenic factors and 
moderately inhibiting the myogenesis [153].   
Tropomodulin consists of an N-terminal tropomyosin-binding 
α-helix1 and α-helix3, Tropomyosin (TM)-dependent actin-binding α-
helix2, and C-terminal leucine-rich repeat (LRR) regions and TM-
independent actin capping region [154]. The recent study on the 
structure of tropomodulin-actin complex reveals that the actin-binding 
sites of tropomodulin bind two actin monomers separately on the 
pointed end of the actin filament, thereby blocking further elongation 
of the filament [155]. Besides interacting with the pointed end of the 
actin filament, tropomodulins interact with tropomyosin through two 
tropomyosin-binding sites located at the N-terminal regions [156]. 
Tropomodulin prevents the loss of actin from the pointed end of 
the filament resulting in slow turnover rate of actin filaments [144]. 
Tropomodulin binds to the actin and interacting partner, tropomyosin, 
which runs along the length of the filament forming a co-polymer [157]. 
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Over 40 tropomyosins are known and the tropomodulins show 
preferential binding to specific tropomyosin [158]. This interaction is 
likely to link with the phosphorylation of Tmod3 in order to form a 
specific type of actin filament in the sub-membranous region.  Actin 
filaments are composed of either two stranded actin polymer or a co-
polymer of actin and tropomyosin [158]. Cytoskeletal actin filaments 
and many tropomyosin isoforms are largely, if not entirely, composed 
of homo-polymers of specific tropomyosin dimers which provide 
structural homogeneity to the actin filament. Moreover, the functional 
capacity of the actin filament is determined by the type of tropomyosin 
dimer bound to the actin filament as it regulates the nature of the 
interaction with other actin binding proteins and myosin motors [158-
160].  
Recently, it has been reported that Tmod3 shows a very clear 
preferential binding to the actin filament with the tropomyosin, 
Tm5NM1/2 in adipocytes [51]. In case of L6 muscle cells, all five 
isoform of tropomyosins Tm1, Tm2, Tm3, Tm4 and Tm5NM1/2 are 
expressed but their interaction with Tmod3 is still unclear. The L71D 
mutation in Tmod3 destroys the formation of hydrophobic surface 
without affecting TM binding capacity; however, it reduces the actin 
capping ability [161]. It has been demonstrated that Tmod3 binds to 
actin monomers not only the residues within the N-terminal actin-
binding site but also over the extended interface [162]. The initial 
phosphorylation of Tmod3 leads directly to the production of specific 
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actin filaments with specific functional attributes [158]. In addition, 
Tmod3-mediated actin remodeling has been shown to play a crucial 
role in definitive erythropoiesis to enhance erythroblast survival, 
erythroblast macrophage adhesion, cell cycle exit, F-actin assembly 
and remodeling in enucleation [150].  
However, mechanism regulating muscle contraction, which is 
believed to be mainly mediated by AMPK signaling, is not clearly 
elucidated. Therefore, investigating the interaction between Tmod3 and 
AMPK in regulating GLUT4 translocation and glucose transport in the 
context of skeletal muscle will provide new mechanistic insights in 



























Figure 1.12 Schematic diagram of structural domains of Tmod3 






























Blood glucose, the main source of energy to the body, must be 
controlled within narrow limits. The blood glucose level is regulated by 
gluconeogenesis and glycolytic pathways that add and remove glucose 
respectively from the circulation. In the post-absorptive state, the 
glucose release from the liver is balanced by glucose clearance by 
nervous system and peripheral tissues. However, postprandial glucose 
entry through digestive system can create imbalance resulting in 
hyperglycemia. In order to counter the rise in blood glucose, the 
pancreatic β-cells secrete insulin resulting in a reduced hepatic glucose 
output and increased glucose uptake by insulin sensitive peripheral 
tissues like brain, adipocytes and skeletal muscles. Besides the 
reduction in hepatic glucose output, glucose clearance by skeletal 
muscle is quantitatively more important as it accounts for up to 90% of 
the clearance of glucose load [163]. 
Studies have shown that both insulin and muscle contractions 
mediate translocation of glucose transporter GLUT4 to the plasma 
membrane for glucose uptake in skeletal muscles [164]. It has been 
shown that plasma membrane and t-tubule directed GLUT4 secretory 
vesicles translocation is involved in stimulating glucose transport in 
contracting muscles [165-167]. In skeletal muscle, besides GLUT4, 
GLUT isoforms such as GLUT1 and 5 are also expressed but at much 
lower levels than GLUT4. The virtual absence of contraction induced 
glucose transport in mice muscles, in which GLUT4 is not expressed, 
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indicates their negligible role in contraction induced glucose uptake [14, 
168].  
The recent study has been shown that Tropomodulin3 (Tmod3), 
actin capping protein that blocks the elongation and de-polymerization 
of the actin filaments at the pointed end [169], plays a vital role in 
GLUT4 translocation and glucose uptake under insulin stimulation in 
3T3-L1 adipocytes upon phosphorylation at S71 by Akt2 [51]. The 
majority of known phosphorylation sites on Tmod3 lie within the Akt2 
consensus motif and are phosphorylated by insulin stimulation. 
However, little has been elucidated concerning other mechanisms to 
enhance the GLUT4 translocation than the insulin signaling system. 
The most commonly prescribed anti-diabetic drug metformin has been 
reported to reduce circulating glucose levels in insulin-resistant patients 
through activation of AMPK [82, 83]. This additional activation of AMPK 
at peripheral sites may provide further beneficial effects in reducing the 
risk for type 2 diabetes and obesity. AMPK and other kinases may also 
phosphorylate Tmod3, and therefore the presence of additional 
phosphorylation sites was predicted. 
It is well understood that the insulin promote glucose uptake in 
muscles and adipocytes by PI3K/Akt signaling pathway and muscle 
contraction may involve multiple molecules including AMPK [170]. 
AMPK plays a major role as a master regulator of cellular energy 
homeostasis. Due to its crucial role as a central regulator of both 
glucose and lipid metabolism, AMPK is considered to be a potential 
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therapeutic target for the treatment of metabolic disorders like diabetes 
mellitus and obesity. Despite the fact that, the skeletal muscle glucose 
uptake plays a vital role in normal conditions, in insulin resistance, and 
type 2 diabetes mellitus, the details of GLUT4 translocation and the 
intracellular signaling involved have not been fully understood.  So, 
identification of AMPK substrate in the regulation of glucose transport 
and its role in GLUT4 translocation will provide new mechanistic 
insights in glucose homeostasis dysregulation. 
The main objective of the study is to identify a novel AMPK 
substrate and characterize its functional role in activated-AMPK-
mediated GLUT4 translocation and glucose uptake in myoblasts. 
To achieve the main objective, the specific objectives are; 
1. To determine whether Tmod3 is an AMPK substrate. 
2. To study the role of Tmod3 in activated-AMPK-mediated GLUT4 
translocation and glucose uptake. 
3. To understand how phosphorylation of Tmod3 by activated-
AMPK regulates actin remodeling which is required for GLUT4 







CHAPTER II  
MATERIAL AND METHODS 
2.1 Antibodies, Plasmids, and Primers  
All the antibodies, plasmids and primers used in this study were listed 
in Table.  
Table 2.1.1 
 List of antibodies used in the study 







Anti-FLAG Mouse WB 1:1000 Sigma/F1804 
Anti-Tubulin Mouse WB 1.:4000 Sigma/T5168 








































Mouse WB/IP/IF 1:1000 R&D Systems 








Anti-γTm9d  Mouse WB/ Detection  
of Tm5NM1 
1:1000 Peter W. 
Gunning 
Anti-δTm9d  Rabbit WB/ Detection  
of Tm4 
1:1000 Peter W. 
Gunning 
Anti-CG1  Mouse WB/ Detection  
of Tm1 
1:1000 Peter W. 
Gunning 
Anti-αTm9d  Mouse WB/ Detection  
of Tm1, 2, 3, 
5a, 5b & 6 




 List of plasmids and primers used in the study 


































































































































































































NheI + HpaI 
cut, ligate into 
pLenti-hiko-
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2.2 Cell Culture 
L6 myoblasts ATCC (American Type Culture Collection) (CRL-1458) 
were cultured and differentiated into myotubes according to standard 
protocols. Briefly, L6 myoblasts were cultured in α-MEM (Cat. No: 
12571071/63, GIBCO, Life Technologies) supplemented with 10% heat 
inactivated fetal bovine serum (Cat. No: 10500-064, GIBCO, Life 
Technologies) and 1% Penicillin-Streptomycin (10,000 U/mL) (Cat. No: 
15140122, ThermoFisher Scientific) at 370C and 5% CO2. 4X10
4/mL 
cells were seeded in 12-well plates and two days later after nearly 70% 
confluence, cells were washed with warm PBS twice and switched to 
differentiation medium containing 2% fetal bovine serum and 17.8mM 
NaHCO3 for 4 days. The medium was changed every 24 hours.  
HEK293T cells were cultured in DMEM (4500mg/L glucose and 
110mg/L sodium pyruvate) supplemented with 10% fetal bovine serum 
and 1% Penicillin-Streptomycin. 
2.3 Lentivirus Packaging and Infection 
Lentiviruses were produced by co-transfection of HEK293T cells with 
lentiviral expression and packaging plasmids using the calcium 
phosphate transfection method as described [171, 172]. Viral 
supernatant was collected after 48 hours of transfection and 
centrifuged at 1000Xg for 5 minutes and filtered through 0.45µm filter. 
The viruses were further concentrated by ultracentrifugation using 
SW41 swinging rotor in Beckman Coulter Optima-L-100 XP at 
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116,000Xg for 2 hours at 40C. L6 myoblasts were transduced with 
titrated viruses in the presence of 8µg/mL of polybrene 
(Hexadimethrine bromide, Cat. No: 107689-10G, SIGMA-ALDRICH). 
The growth medium was replaced with normal growth medium after 24 
hours of transduction. 
2.4 Protein Purification 
2.4.1 Preparation of FLAG-tagged proteins from HEK293T cells 
FLAG tagged proteins were expressed in HEK293T cells and the cells 
were lysed in TNET buffer (50mM Tris-Cl, pH 7.5, 150mM NaCl, 10mM 
NaF, 1mM EDTA, 1% Trition X-100) containing 2mM Na3VO4 (Sodium 
Orthovanadate) and 1mM PMSF (phenylmethylsulfonyl fluoride)  and 
1X protease inhibitor cocktail tablet (Roche). The cleared supernatant 
was purified using anti-FLAG M2 Affinity gel (Cat. No: A2220, SIGMA-
ALDRICH). Proteins were subsequently eluted with 3XFLAG peptide 
(Cat. No: F4799, SIGMA-ALDRICH) in TBS buffer (50mM Tris-Cl, pH 
7.5, 150mM NaCl). Total protein concentrations in the samples were 
measured using Bradford assay. 
2.4.2 Recombinant GST-fusion protein purification 
Full length mouse Tmod3-WT (Wild Type) and mutants were inserted 
in-frame in the linker region of pGEX-KG vector in order to encode 
fusion proteins with GST (Glutathione S-transferase) in the N-terminus. 
GST fusion Tmod3-WT and mutants were expressed in BL21 E. coli 
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(Escherichia coli) (Cat. No: C2530H, New England Biolabs) and 
induced with 1mM IPTG (Isopropyl-β-D-Thiogalactopyranoside) for 
protein production. The bacteria were harvested when OD600 of the 
bacterial growth reached approximately 1.00. The lysates were 
harvested and purified using standard protein purification protocol. 
Briefly, bacteria pellet were re-suspended in Buffer A (20mM Tris-Cl, 
pH 8.0, 0.1M NaCl, 1mM DTT (Dithiothreitol) containing 1mM PMSF 
and 1X protease inhibitor cocktail tablet and incubated with 0.25mg/ml 
lysozyme on ice for 30min. The bacteria lysates were sonicated on ice 
using an ultrasonic processor Vibra-Cell VCX130 (SONICS & 
MATERIALS, Inc) with 8 cycles of 30 seconds pulse followed by 10 
second break at Amplitude output of 40% for 4 minutes. The lysates 
were treated with 0.5% Triton X-100 and rocked at 40C for 15 minutes. 
The lysates were then cleared by centrifugation at 16,000Xg, at 40C for 
30 minutes. In the meanwhile, Glutathione-Sepharose 4B beads (GE 
Healthcare) were equilibrated in Buffer A containing 0.1% Triton X-100. 
The pre-equilibrated beads were incubated with clear supernatant for 1 
hour at 40C.  The glutathione beads bound GST-fusion proteins were 
eluted by thrombin cleavage (GE Healthcare) in TTB buffer (20mM 
Tris-Cl, pH 8.0, 2.5mM CaCl2, 150mM NaCl). Thrombin was removed 
using Benzamidine-Sepharose beads (GE Healthcare) and thrombin 
free proteins were further concentrated using centrifugal filters (Amicon 




2.5  Detection of Phospho-Ser25 of Tmod3 by LC-MS/MS 
In-gel digestion and Nano-Electrospray Ionization-tandem mass 
spectrometry, and Mass Spectrometry data analysis were performed 
by Dr. Bi Xuezhi from Bioprocessing Technology Institute (BTI), 
A*STAR, Singapore. 
2.5.1 In-gel digestion and Nano-Electrospray Ionization-tandem 
mass spectrometry 
Phosphorylation of Ser25 of Tmod3 was detected by LC-MS/MS as 
described previously with brief modifications [173]. Briefly, FLAG-
tagged Tmod3 proteins were purified from HEK293T transiently co-
expressing FLAG-Tmod3 and constitutively active form of AMPK (Myc-
AMPK-CA) using anti-FLAG M2 Affinity gel. Proteins were eluted in 2x 
Laemmli buffer, heated at 950C for 10 minutes and separated using 
12% precast gels (Bio-Rad Mini-PROTEAN®TGXTM). The gel was 
stained with 0.1% Coomassie Brilliant Blue R250. About 40kDa gel 
bands which were corresponding to Tmod3 were excised, de-stained, 
de-hydrated with acetonitrile, treated with 25mM DTT in 50mM 
ammonium bicarbonate at 560C for 25 minutes and alkylated in 55mM 
Iodoacetate for 30 minutes in the dark at room temperature. Samples 
were then incubated with 1μg trypsin for 16 hours at 37 °C. Then after, 
the gel plugs were digested with 10ng/μl mass spectrometry grade 
trypsin gold (Promega) in 25mM ammonium bicarbonate overnight at 
370C. Peptide mixtures were extracted with 20mM Ammonium 
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bicarbonate, then with 50%(v/v) acetonitrile, 5%(v/v) formic acid in 
H2O. The pooled peptides, thus evaporated to dryness using 
SpeedVac, were dissolved in 5μl of 2%(v/v) methanol, 1%(v/v) formic 
acid with 50mM citric acid for enhancing the detection by LC-ESI-
MS/MS.  
Mass spectrometry (MS) analysis was performed on a LTQ-
Orbitrap Velos Pro ETD Mass Spectrometer (Thermo Fisher Scientific, 
San Jose, CA) that was equipped with nanoACQUITY UPLC system 
(Waters Milford, MA), Xcalibur 2.2 SP1.48 and LTQ Tune Plus 2.7 
instrument control. 5μl of peptides were desalted for 5 minutes with 
0.1% (v/v) formic acid in water and 1% (v/v) acetonitrile in mobile 
phase at the rate of 8μL per minute. Nano-reverse-phase liquid 
chromatography, in nanoACQUITY UPLC BEH 1301.7μm C18 column, 
75μmx200m, was used to separate desalted peptides keeping the flow 
rate of 0.3μl/min at 350C. Nanospray in positive ion mode at 1.8kV was 
used for ionization. Data-dependent scanning tandem mass 
spectrometry was used to obtain spectra with one full MS scan from 
300 to 1,800m/z at resolution of 60,000, followed by HCD Orbitrap 
tandem MS scans of ten most intensive peptide ions with normalized 
collision energy of 35v at a resolution of 15,000. 
2.5.2 Mass Spectrometry data analysis 
SequestHT and PhosphoRS3.0 in Protein Discoverer 1.4 SP1 software 
(ThermoScientific ),  were used to analyze Tandem mass spectrometry 
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data. MS raw data were also analyzed by database search using 
UniProtKB/Swiss-Prot, and annotation of the phospho-peptide tandem 
MS/MS using PEAKS studio 7.0 software (Bioinformatics Solutions 
Inc.). ± 5 ppm and ± 0.2 Da of the peptide and fragment ion mass 
tolerances were used respectively.  Carbamido-methylation of cysteine 
was included as a fixed modification, oxidation of methionine, 
phosphorylation of serine, threonine and tyrosine were selected as 
dynamic and variable modification. Two missed cleavages were 
allowed for searching the data.  
2.6 In Vitro GST Pull-Down Assay 
The glutathione beads bound GST-fusion proteins were equilibrated 
with TNET buffer. The beads and cell lysates containing 2mg proteins 
were rocked at 40C for overnight. The beads were washed with TNET 
buffer and eluted using 2X Laemmli sample buffer. The samples were 
subjected to SDS-PAGE (Sodium Dodecyl Sulfate - Polyacrylamide 
Gel Electrophoresis) and western blot analysis. 
2.7 In Vitro Protein Kinase Assay 
In vitro kinase assays were performed on purified FLAG-tagged 
Tmod3 WT and mutant proteins. Briefly, 1μg of FLAG-Tmod3 and 1μg 
recombinant AMPK (α1/β1/γ2)((SIGMA-ALDRICH, Cat. No: A1358) 
were incubated in 20μl of volume reaction in kinase buffer (25mM Tris-
Cl, pH 7.5, 5mM β-Glycerophosphate, 2mM DTT), 0.1mM Na3VO4, 
10mM MgCl2) containing 0.2mM ATP. The kinase reaction was 
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incubated at 30 °C for 30 minutes and boiled in 30μl 2X Laemmli 
sample buffer and separated by SDS-PAGE.  Phosphorylation signals 
were detected using anti-phospho-serine antibody. For 
autoradiography, the sample mixtures were incubated in the kinase 
buffer with 10μCi [32P] γ-ATP (PerkinElmer, SG) for 30 minutes at 
30 °C. The samples were then subjected to SDS–PAGE and 
autoradiography. 
2.8 In Vitro Actin Cross-linking Assay 
Purified non-muscle actin of human platelet origin was purchased from 
Cytoskeleton, Inc. The protein sample was spinned at 300,000X g for 2 
hours at 4 °C in order to remove aggregates. Then the protein 
concentrations were determined by spectrophotometry. Crosslinking of 
G-actin and Tmod3-WT, and mutants was performed according to the 
standard protocol with some modifications [162]. Briefly, G-actin and
Tmod3 proteins were exchanged into a buffer containing 5mM HEPES 
(pH 7.5), 0.1mM CaCl2, 0.2mM ATP and 0.2mM DTT using protein 
desalting spin columns (Pierce). G-actin and Tmod3 were mixed at 
equimolar ratio at concentrations between 10 and 20 μM for 20 min at 
room temperature. Freshly prepared cross-linking stock solutions of 1-
Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC; Pierce) and N-
hydroxylsulfosuccinimide (NHS; Pierce) were added to the reaction at a 
final concentration of 1mM and incubated for 45 minutes at room 
temperature. Reactions were terminated by adding 2X LB and the 
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samples were subjected to SDS–PAGE. Assays using GST-
Tmod3 proteins were performed similarly in case of glutathione beads 
bound proteins. Gels were either transferred to nitrocellulose for 
immunoblotting with antibodies to Tmod3 or actin or stained with 
Coomassie Brilliant Blue R-250, as previously described [149]. 
2.9  Radioactive Glucose Uptake Assay 
2-Deoxyglucose uptake measurements were carried out as described 
previously [174] with some modifications. Briefly, L6 myoblasts or 
myotubes were deprived of serum for 2 hours. Following all 
stimulations and inhibitions cell monolayers were washed thrice with 
KRPH (Krebs-Ringer Phosphate – Hepes, pH 7.4) buffer  (136mM 
NaCl, 20mM HEPES (pH 7.4), 5mM sodium phosphate buffer 
(NaH2PO4–Na2HPO4·7H2O, pH 7.4), 4.7mM KCl, 1mM MgSO4, 1mM 
CaCl2) [175] and any remaining liquid was aspirated. Cells were then 
incubated for 5 minutes in KRPH buffer containing 10μmol/l unlabeled 
2-deoxyglucose and 10μmol/l [3H]-2-deoxyglucose (1μCi/ml) in the 
absence of AICAR and inhibitors, unless otherwise indicated. The 
reaction was terminated by washing thrice with cold PBS. The 
radioactivity was determined by lysing the cells with 0.05N NaOH, 
followed by liquid scintillation counting using PerkinElmer counter. 
Total protein was determined by the Bradford method. Nonspecific 
uptake was determined in the presence of 10μmol/l Cytochalasin B and 
subtracted from all experimental values. The glucose uptake values are 
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expressed as “pmol radioactive 2-deoxyglucose taken up per minute 
and per mg protein.” 
2.10 Fluorescence Microscopy 
Co-localization studies were carried out as described previously [51, 
176]. Briefly, L6 myoblasts plated on 0.1% gelatin-coated coverslips 
were serum starved for 2 hours before AICAR treatment. Cells were 
fixed with 4% paraformaldehyde of pH 7.4, washed with ice cold PBS 
and blocked with PBS containing with 5% goat serum (Cat. No: 
16210072, GIBCO Life Technologies) and 0.02% sodium-azide for at 
least 1 hour. Cells were then permeabilized with 0.01% Triton-X 100 in 
PBS and stained with relevant antibodies followed by Alexa Fluor 
secondary antibodies accordingly. The coverslips were mounted with 
DAKO mounting medium (DAKO) after washing with PBS. Optical 
sections of each samples were taken through sequential scans at 
relevant wavelengths (488nm and 561nm) using a Nikon A1R-A1 
confocal laser microscope system with X100 NA/1.40 CFI Plan APO 
VC oil-immersion objective. TIRFM setup was based on Nikon Eclipse-
Ti inverted microscope with two EMCCD cameras (1,002X1,002 pixels, 
8X8μm, 14-bit, Andor iXonEM+885; Andor Technologies) capable of 
capturing two channels (TIRF laser 488nm; TIRF laser 561nm) 
simultaneously. Both TIRF and epifluorescence images were captured 
using X100 NA/1.49 APO TIRF oil-immersion objective. Immersion oil 
(ND=1.515, Nikon) was used to bridge the optical contact between the 
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coverslip and the objective. The penetration depth of the evanescent 
field is estimated to be ~200nm. Images were acquired with no binning; 
at 13MHz, the readout rate with average exposure times vary between 
100 and 300ms. Cells were seeded to grow in 35-mm glass-bottom 
dishes (MatTEK) for 2 days before imaging. Cells were serum starved 
for 2 hours and treated with AICAR in a Tokai Hit temperature 
controlled incubation box at 37 °C supplemented with 5% CO2. 
2.11 Myc-GLUT4-mCherry Translocation 
The slides were prepared as described in section 2.10. Briefly, after the 
AICAR treatment the L6 cells were fixed and blocked in non-
permeabilized condition. Then the cells were incubated with primary 
mouse anti-Myc Ab (9E10) for overnight and with Alexa Fluor 488-
conjugated anti-mouse secondary antibody for 1 hour at 40C. Mounted 
samples were subjected to confocal imaging. Nikon Element software 
was used for quantitative measurements of GLUT4 
vesicle translocation. Briefly, the entire ventral surface of each cells 
expressing Myc-GLUT4-mCherry was selected for measurement of 
fluorescence intensity of both mCherry and Myc-signals after removal 
of background fluorescence. The ratio of cell surface to total 
GLUT4 was quantified by detecting cell surface GLUT4 through anti-
Myc fluorescence immunolabelling and total GLUT4 through mCherry 
fluorescence in non-permeabilized L6 cells. Data in each group were 
normalized and expressed as a percentage of AICAR-treated control 
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cells. TIRF/epifluorescence analysis for fixed cells was performed [115, 
177]. Under non-permeabilized conditions, the ratio of TIRF-Myc/Epi-
mCherry was acquired by dividing the fluorescence intensity of TIRF-
Myc signal for each cell by that of the Epi-fluorescence GLUT4-
mCherry. Data in each group were averaged and the ratio of TIRF-
myc/Epi-mCherry in Scramble control group was set as 1 for group 
comparison. 
2.12 TIRFM-based Actin Remodeling and Analysis 
TIRF based actin remodeling and analysis were done as described 
previously [51]. L6 myoblasts expressing Lifeact-tdTomato were serum 
starved for 2 hours and imaged using TIRFM. AICAR (2mM) was 
added at zero time point and TIRF images were taken over 30 minutes 
with an interval of 15 seconds and 121 total readings. Two independent 
ways of measurement were used to analyze the actin remodeling. (1) 
Measurement of TIRF-Lifeact-tdTomato on the cell periphery: as for 
this analysis, it was particularly focused on the AICAR-stimulated 
buildup or enrichment of cortical actin at the cell periphery. To quantify, 
multiple boxes of region of interest (L X W: 5 X 5, 25μm2 per region of 
interest (ROI)) spanning across the boundary of cell periphery were 
used to measure the fluorescence intensities of RAW images over 
time. In order to take into account the membrane reorganization in the 
time course, each ROI was selected to include a portion of the cell 
periphery and partial background. TIRF intensities of all ROIs were 
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measured over time, all the reading were normalized to the intensity 
measured at zero time point after removing  the background 
fluorescence, and the averaged  values were plotted against the time 
so as to indicate the time course of actin remodeling under AICAR 
stimulation. The extent of cortical actin rearrangements is measured 
without considering the behavioral changes in actin. Events of 
membrane remodeling could be distinguished from the events of 
thickening of cortical actin. (2) Measurement of the TIRF-Lifeact-
tdTomato on the ventral regions of the cell and away from the cell 
edge: ventral regions of each individual cell, excluding the peripheral 
regions of the cell were manually selected in Nikon Element software 
and subjected to time course analysis as described in (1) Measurement 
of TIRF-Lifeact-tdTomato on the cell periphery. The extent of ventral 
actin polymerization was assessed over time without taking into 
account the changes in membrane ruffling activity and peripheral actin 
structures.  
2.13 Gene Expression Analysis by RT-PCR 
Total RNA from L6 myoblasts or myotubes was extracted using 
RNeasy Mini Kit (Cat. No: 74016, Qiagen). First-strand cDNA synthesis 
was performed using one μg of RNA after DNase I treatment (Applied 
Biosystems TaqMan Reverse Transcription Reagents). The samples 
were diluted and cDNA was subjected to real-time PCR using SYBR 
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Green dyes along with appropriate primers. 2−ΔΔCt method was used to 
calculate the relative expression of mRNA abundance . 
2.14 Mouse Work 
Mice used in this study were maintained in animal facility of Biological 
Resource Centre, A*STAR. All the animal experiments were conducted 
in accordance with the regulations of Institutional Animal Care and Use 
Committee (IACUC #161122, SBIC-LMM, A*STAR). C57BL6/J male 
mice, 5–7 weeks old, were injected i.p. with 250mg/kg AICAR in sterile 
0.9% NaCl or with 0.9% NaCl as previously described [178]. Mice were 
then killed after 6 hours of treatment, and the gastrocnemius muscle 
was harvested for RNA analysis and Western analysis. 
2.15 Statistical Analysis 
Data were expressed as means ± SEM unless otherwise stated. 
Statistical analyses were performed using one-way analysis of variance 
for group comparisons or unpaired Student’s t-test. The levels of 
statistical significance were presented as asterisks and defined in each 
figure legend together with the name of the statistical test accordingly. 
The graphical data were analyzed using Microsoft Excel 2010 and 





CHAPTER III  
RESULTS 
3.1 Identification of Tropomodulin3 as a novel AMPK substrate  
3.1.1 Tropomodulin3 is a novel AMPK substrate 
Tropomodulin is an actin capping protein that binds and caps the 
pointed end of actin filaments specifically, regulating the length, 
stability, architecture and geometry of membrane cortical actin. Unlike 
other isoforms, Tmod3 is ubiquitously expressed in a variety of tissues 
and cell types. Tmod3 was found to be expressed in L6 myoblasts and 
differentiated myotubes.  Tmod3 expression level was found to 
consistent throughout the myogenic differentiation, as shown by RT-
qPCR and Western blot analysis (Figure 3.1.1A-B).  
 AMPK phosphorylates downstream targets at conserved Ser/Thr 
residues within a consensus sequence motif, which has bulky 
hydrophobic residues at the −5 and +4 positions (5 residues N terminal 
and 4 residues C terminal to the phosphorylated serine/threonine) and 
basic residues at −4 or −3, or both positions [179, 180]. It is a serine 
residue that is phosphorylated even though threonine can also be 
phosphorylated by AMPK in synthetic peptide substrates. The 
importance of the motif (Φ-[β,X]-X-X-S/T-X-X-X-Φ), where Φ is 
hydrophobic and β is basic, was confirmed previously by using variant 
synthetic peptides substrates [179, 181]. The protein databases were 
screened for proteins with AMPK consensus motif sequences by using 
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the bioinformatics tool Scansite, Phosphosite, Phosphomouse and 
neXtProt in an effort to identify novel pathways that may be regulated 
by AMPK. As predicted, one of the candidates identified is Tmod3, with 
putative phosphorylation site at Serine 25 (S25) amino acid residue. 
Sequence analysis revealed the presence of an AMPK consensus 
phosphorylation motif [LLGKLS*ESEL, Ser25] just before α-helix1 
region at the N terminus in Tmod3. The phosphorylation motif is 
present in both Tmod2 and Tmod3 but not in Tmod1 and Tmod4 
(Figure 3.1.1C). 
The consensus AMPK phosphorylation motif (Φ-[β,X]-X-X-S/T-
X-X-X-Φ) was found to be conserved in Tmod3 sequence of human, 
mouse and rat (Figure 3.1.1C). In the consensus recognition motif, Φ 
refers to a hydrophobic residue (M, L, I, F, or V) and β to a basic 
residue (R, K, or H). Hydrophobic and basic residues are believed to 
be important in recognition of the target sequences.Tmod3 has 
conserved hydrophobic residues at the −5 (L) and +4 (L) positions. 
In vitro GST-pull down assay was performed to check whether 
there is direct Tmod3-AMPK interaction. Recombinant proteins, GST 
and GST-Tmod3, expressed in bacteria were captured by glutathione 
beads and incubated with cell lysates of HEK293T transiently 
expressing Myc-tagged mouse AMPK-α2. Figure 3.1.1D shows that 
GST-Tmod3 pulled down AMPK. Collectively, these data suggest that 
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Figure 3.1.1 Tropomodulin3 is a novel AMPK substrate in 
myocytes 
(A) Consistent expression of Tmod3 in L6 myoblasts and differentiated 
myotubes. Expression of various genes were analyzed in both pre and 
post differentiated L6 myocytes by RTqPCR (n=5 per group). (B) 
Protein expression at different stages of L6 myoblast differentiation 
was examined from day zero to day six. (C) Schematic diagram of 
different domains of Tmod3 and identified phosphorylation site are 
shown in the upper panel. AMPK consensus sequence is present in 
both Tmod2 and Tmod3 but not in Tmod1 and Tmod4 as shown in the 
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Consensus AMPK phosphorylation motif  
Tmod3 [ϕ-β-X-X-XS/T-X-X-X-ϕ, ϕ= M, V, L, I, F and β= K, R, H] 
Human  L-L-G-N-L- S -E-T-E-L 
Mouse  L-L-G-K-L- S -E-S-E-L 
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3.1.2 AICAR-stimulated Tmod3 phosphorylation is regulated by 
AMPK signaling pathway  
To seek evidence of Tmod3 as a potential AMPK substrate, FLAG-
Tmod3-WT was co-expressed with or without mouse Myc-AMPK-α2-
WT in HEK293T cells and subjected to AMPK activation using AICAR 
and 2-Deoxyglucose at different time points. The samples were 
subjected to immune-precipitation using anti-FLAG M2 affinity gel. 
Tmod3 phosphorylation rapid peaked at 15 minutes in case of AICAR 
treatment and at 30 minutes in case of 2-Deoxyglucose treatment and 
decreased moderately through the treatment period, in conjunction with 
the phospho-AMPK (Figure 3.1.2-A and B). In addition to AMPK 
activation using AICAR and 2-Deoxyglucose, FLAG-Tmod3-WT was 
co-expressed with either constitutively active (Myc-AMPK- α2-CA) or 
kinase inactive (Myc-AMPK- α2-DN, K45R mutation) AMPK and 
subjected to immuno-precipitation using anti-FLAG M2 affinity gel. 
FLAG-Tmod3-WT was phosphorylated in the presence of constitutively 
active form of AMPK but not kinase inactive form of AMPK (Figure 
3.1.2-C). Furthermore, Mass Spectrometry analysis of purified Tmod3 
from HEK293T cells co-expressing FLAG-Tmod3-WT and Myc-AMPK- 
α2-CA revealed that AMPK phosphorylated Tmod3 at Ser25 (Figure 
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Figure 3.1.2 Tropomodulin3 phosphorylation is regulated by 
AMPK signaling pathway 
(A) Kinetics of AICAR induced phosphorylation of Tmod3. AICAR 
induces phosphorylation of Tmod3 in AMPK dependent manner. 
HEK293T cells co-expressing FLAG-Tmod3-WT and Myc-AMPK-α2-
WT were either untreated or treated with AICAR (2mM) for indicated 
time periods. Anti-Phospho Serine antibody was used for immuno-
precipitation of phosphorylated Tmod3 from the cell lysates followed by 
immuno-blotting with anti-FLAG antibody. (B) 2-DG induces 
phosphorylation of Tmod3 in AMPK dependent manner. HEK293T cells 
co-expressing FLAG-Tmod3-WT and Myc-AMPK- α2-WT were either 
untreated or treated with 2-DG (100mM) for indicated time periods. 
Anti-Phospho Serine antibody was used for immuno-precipitation of 
phosphorylated Tmod3 from the cell lysates followed by immuno-
blotting with anti-FLAG antibody.  (C) Tmod3 interacts with 
constitutively active (CA) AMPK but not with kinase inactive (DN) 
AMPK and gets phosphorylated. AMPK mediated phosphorylation of 
Tmod3 in HEK293T cells following co-expression of FLAG-Tmod3-WT 
with either AMPK. (D) Identification of Ser25 residue in Tmod3 as the 
phosphorylation site of AMPK with MS as described in Section 2.5. 
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3.1.3 AMPK phosphorylates Tmod3 in vitro  
To determine Tmod3 as a direct or indirect AMPK substrate, FLAG-
Tmod3 was expressed in HEK293T cells and immune-precipitated with 
anti-FLAG M2 affinity gel. FLAG-Tmod3 proteins were eluted using 
3XFLAG peptide before subjected to in vitro kinase assay in presence 
of recombinant AMPK and γ-32P-ATP. Figure 3.1.3-A shows that AMPK 
induces Tmod3 phosphorylation showing that Tmod3 is AMPK 
substrate. Besides Autoradiography, immuno-precipitation using anti-
Phospho Serine antibody and immune-blotting using anti-FLAG 
antibody, in case of FLAG-Tmod3 over-expression with or without 
constitutively active form of Myc-AMPK-α2, showed that Tmod3 was 
phosphorylated by AMPK. To validate the mass-spectrometry data, 
FLAG-Tmod3-WT and its variants were over-expressed in HEK293T in 
presence and absence of Myc-AMPK- α2-CA and were pulled down 
using anti-phospho-Serine antibody conjugated to protein A/G 
Sepharose beads and phosphorylated Tmod3 were detected using 
anti-FLAG antibody (Figure 3.1.3-B). As shown in Figure 3.1.3-C 
Tmod3-WT and Tmod3-S27A, but not Tmod3-S25A and Tmod3-
S25A/S27A, were phosphorylated, confirming that Ser25 is the site of 
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Figure 3.1.3 Tropomodulin3 is phosphorylated by AMPK in vitro 
(A) AMPK phosphorylates Tmod3 in vitro. Purified full-length mouse 
Tmod3 was incubated with recombinant AMPK and γ-32P-ATP in an in 
vitro kinase assay. The samples were analyzed by SDS-PAGE and 
autoradiography. (B) AMPK phosphorylates Tmod3 at Ser25. FLAG-
Tmod3 and its variants were co-expressed with Myc-AMPK- α2-CA 
were pulled down using anti-phospho-Serine antibody conjugated to 
protein A/G Sepharose beads and phosphorylated Tmod3 signals were 
detected using anti-FLAG antibody. (C) Ser25 but not Ser27 is the 
phosphorylation target of AMPK as demonstrated by autoradiography 
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3.1.4 AICAR-stimulated phosphorylation of Tmod3 in L6 myotubes 
and in mouse Gastrocnemius muscle tissue in vivo  
In order to further confirm the phosphorylation of Tmod3 under AMPK 
activation, phosphorylation was examined in L6 myotubes and mice. 
Well differentiated L6 myotubes of day four were treated with or without 
AICAR after 2 hours of serum starvation. The cell lysates were 
immuno-precipitated with anti-Tmod3 rabbit antibody conjugated to 
protein A/G Sepharose beads and phosphorylation of Tmod3 was 
detected by anti-phospho-Serine mouse antibody. Increased Tmod3 
phosphorylation was observed in case of AMPK activation (Figure 
3.1.4-A). 
Likewise, for in vivo studies, C57BL/6 mice were fasted 
overnight and subjected to intraperitoneal injection with either saline 
(0.9% NaCl) or AICAR (250mg/kg body weight). After 6 hours, mice 
were sacrificed and gastrocnemius muscle tissues were extracted. The 
tissue lysates were subjected to immuno-precipitation using anti-
Tmod3 rabbit antibody conjugated to protein A/G Sepharose beads 
and phosphorylation of Tmod3 was detected by anti-phospho-Serine 
mouse antibody. Increased Tmod3 phosphorylation was observed in 
gastrocnemius muscle tissue from mice treated with AICAR, compared 
to those treated with saline (Figure 3.1.4-B). These data demonstrate 
that Tmod3 is a novel AMPK substrate and its phosphorylation is 






Figure 3.1.4 AMPK enhances Tropomodulin3 phosphorylation 
within L6 myotubes and skeletal muscle in vivo 
(A) Lysates from L6 myotubes treated with or without AICAR were 
immuno-precipitated with anti-Tmod3 antibody and phosphorylation of 
Tmod3 was detected with anti-Phospho Serine antibody. (B) Lysates 
from gastrocnemius muscles of wild-type C57BL/6 mice (n=6) with 
either saline (0.9% NaCl) or 2mM AICAR treatment were immuno-
precipitated with anti-Tmod3 antibody and phosphorylation of Tmod3 
was detected with anti-Phospho Serine antibody. Data are 
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3.2 Tmod3 acts downstream of AMPK and its phosphorylation is 
associated with activated-AMPK 
3.2.1 Phosphorylation of Tmod3 and its association with 
activated- AMPK 
Under AMPK activation, a subset of Tmod3 was found to co-localize 
with phospho-AMPK as demonstrated by confocal microscopic imaging 
(Figure 3.2.1-A). Interestingly, the co-localization of Tmod3 with the 
phospho-AMPK was significantly reduced in Tmod3 KD L6 myoblasts 
under AMPK activation (Figure 3.2.1-B).  
Increased interaction of Tmod3 with activated-AMPK and their 
co-localization under AICAR-stimulated condition suggest a shared 
functional site of actions for certain physiological events to occur. 
Moreover, increased phospho-AMPK signals in scramble and Tmod3 
KD myoblasts upon AICAR stimulation suggest that phosphorylation of 
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Figure 3.2.1 Tmod3 undergoes phosphorylation and co-localizes 
with phospho-AMPK in L6 myoblasts in response to AICAR 
stimulation 
(A) L6 myoblasts stably expressing FLAG-Tmod3 were serum starved 
for 2 hours and treated with or without 2mM AICAR for 30 minutes. 
Myoblasts were fixed and permeabilized with 0.1% TritonX-100 in PBS 
before immuno-staining with mouse anti-FLAG and rabbit anti-
phospho-AMPK (Thr-172) antibody followed by Alexa Fluor-488 
conjugated goat anti-mouse and Alexa Fluor-568-Phalloidin conjugated 
goat anti-rabbit secondary antibodies respectively. (B) Consistent 
phospho-AMPK signals in both scramble and Tmod3 KD L6 myoblasts 
under AICAR stimulation. The samples were subjected to confocal 
microscopic imaging. Scale bar: 10μm. Fluorescence intensities were 
quantified along the lines as shown in the right panels. Data are 

























































































































































































































3.3 Role of Tmod3 in regulating AICAR-stimulated glucose 
transport and GLUT4 translocation 
3.3.1 Tmod3 clusters around cortical F-actin and co-localizes with 
GLUT4 at AICAR-induced membrane ruffles 
Tropomodulins are actin capping proteins that block elongation and de-
polymerization of the minus (pointed) end of actin filaments thereby 
regulates the length of actin filaments in muscle and non-muscle cells 
[144]. Tmod3 has been shown to localize preferentially at the F-actin 
rich structures [149]. Tmod3 was associated with phalloidin-labeled 
cortical F-actin and co-localized with GLUT4 at cell periphery under 
AMPK activation condition (Figure 3.3.1-A and B) as demonstrated by 
confocal microscopic imaging. These data suggest the important role of 
Tmod3 in regulating AMPK signaling mediated GLUT4 translocation 
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Figure 3.3.1 Tmod3 is associated with cortical F-actin and GLUT4 
in L6 myoblasts 
(A) L6 myoblasts stably expressing FLAG-Tmod3 were serum starved 
for 2 hours and treated with or without 2mM AICAR for 30 minutes. 
Myoblasts were fixed and permeabilized with 0.1% TritonX-100 in PBS 
before immuno-staining with mouse anti-FLAG and rabbit anti-Actin 
antibody followed by Alexa Fluor-488 conjugated goat anti-mouse and 
Alexa Fluor-568-Phalloidin conjugated goat anti-rabbit secondary 
antibodies respectively. (B) Co-localization of FLAG-Tmod3 and Myc-
GLUT4-mCherry in response to AICAR stimulation. L6 myoblasts 
stably expressing FLAG-Tmod3 and Myc-GLUT4-mcherry were serum 
starved for 2 hours and treated with or without 2mM AICAR for 30 
minutes. Myoblasts were fixed and permeabilized with 0.1% TritonX-
100 in PBS before immuno-staining with mouse anti-FLAG antibody 
followed by Alexa Fluor-488 conjugated goat anti-mouse. The samples 
were subjected to confocal microscopic imaging. Scale bar: 10μm. 
Fluorescence intensities were quantified along the lines as shown in 












































































































































3.3.2 Tmod3 is required for AICAR-stimulated glucose transport 
Tmod3 has been previously shown to be involved in insulin-stimulated 
glucose transport in adipocytes [51]. To investigate the role of Tmod3 
in AMPK-activated glucose transport, lentiviral constructs encoding 
shRNA against Tmod3 and GFP were generated so as to silence the 
endogenous target proteins in L6 myoblasts. [3H]-2-Deoxyglucose 
uptake assay was performed to examine the effect of silencing Tmod3 
on AICAR-stimulated glucose uptake in L6 myoblasts. L6 myoblasts 
and myotubes showed approximately 1.5 folds increase in glucose 
uptake under Insulin and AICAR stimulation as compared to the control 
(Figure 3.3.2-A and B), indicating no significant difference between L6 
myoblasts and myotubes in glucose uptake. As shown in Figure 3.3.2-
C, Tmod3-KD myoblasts displayed a significant reduction in AICAR-
stimulated glucose uptake (scramble + AICAR [1.5 ± 0.09] versus 
shTmod3 + AICAR [0.9 ± 0.04]). Likewise, AMPK inhibitor, Compound 
C (CC) treatment led to significant reduction in glucose uptake in case 
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Figure 3.3.2 Tmod3 is required for AICAR-stimulated glucose 
uptake in L6 myoblasts  
(A-B) Insulin and AICAR have similar effect on glucose uptake in both 
L6 myoblasts and differentiated myotubes. Myocytes were serum 
starved for 2 hours, treated with or without100nM insulin for 20 minutes 
and 2mM AICAR for 30 minutes for [3H]-2-Deoxyglucose uptake assay. 
(C) Scramble and Tmod3-KD L6 myoblasts were serum starved for 2 
hours, treated with or without 2mM AICAR and Compound C (CC) for 
30 minutes for [3H]-2-Deoxyglucose uptake assay. Silencing of Tmod3 
in L6 myoblasts impairs AICAR stimulated [3H]-2-Deoxyglucose uptake. 
Data are presented as mean ± SEM of four independent experiments. 









3.3.3 Tmod3 regulates AICAR-stimulated GLUT4 exocytosis 
Besides insulin, AICAR-activated AMPK induces glucose transport [53, 
182-185]. Activated-AMPK-induced glucose transport is primarily 
mediated by GLUT4 translocation in myocytes [186]. Silencing of 
Tmod3 may lead to disruption of activated-AMPK-mediated GLUT4 
translocation. L6 myoblasts stably expressing Myc-GLUT4-mCherry 
fusion protein with Myc epitope in the first exofacial loop at N-terminus 
and mCherry at C-terminus were used for the detection of GLUT4 upon 
plasma membrane insertion by Myc and total GLUT4 content by 
mCherry in non-permeabilized condition (Figure 3.3.3-A) [51]. GLUT4 
translocated to the plasma membrane under non-permeabilized 
condition was quantified by measuring Myc signal detected by anti-Myc 
antibody and anti-mouse-AlexaFluor-488 over mCherry signal in 
individual myoblasts by confocal microscopic imaging. In scramble 
myoblasts, AICAR-activated-AMPK induced approximately 58% of 
GLUT4 translocation to the plasma membrane. Unlike in control 
myoblasts, Tmod3-KD myoblasts showed significant reduction in 
GLUT4 translocation to the plasma membrane (Figure 3.3.3-B and C) 
suggesting that Tmod3-KD may result in impairment of GLUT4 vesicle 
translocation. These data taken together suggest that Tmod3 is 
required for AICAR-mediated AMPK-induced glucose uptake and 










Figure 3.3.3 Tmod3 is required for AICAR-stimulated GLUT4 
exocytosis 
(A) GLUT4 fusion protein, Myc-GLUT4-mCherry, for the detection of 
GLUT4 translocation to the plasma membrane. (B-C) Silencing of 
Tmod3 inhibits AIAR stimulated GLUT4 translocation. L6 myoblasts 
stably expressing Myc-GLUT4-mcherry were serum starved for 2 hours 
and treated with or without 2mM AICAR for 30 minutes. In fixed and 
non-permeabilized cells, cell surface Myc-GLUT4-mCherry signals 
were detected with anti-Myc mouse monoclonal antibody followed by 
Alexa Fluor-488 goat anti-mouse secondary antibody. The samples 
were subjected to confocal microscopic imaging.  Intensity of Myc at 
plasma membrane was quantified against intensity of total mCherry in 
the whole cell. Data are presented as mean ± SEM of 100 cells in each 
group from three sets of independent experiments. **p<0.01 versus 










































































3.3.4 Role of Tmod3 in GLUT4 translocation  
To investigate the effect of Tmod3 silencing on GLUT4 vesicle 
trafficking and fusion, total internal reflection fluorescence microscopy 
(TIRFM) was applied so as to restrict the field of view only up to 
~200nm from the plasma membrane under non-permeabilized 
condition. Ratio of TIRF-Myc fluorescence to Epi-mCherry fluorescence 
indicates the amount of GLUT4 fused into plasma membrane. AICAR 
stimulated control myoblasts showed intense GLUT4 translocation as 
illuminated by green and red fluorescence intensities in the TIRF zone. 
On the contrary, Tmod3-KD myoblasts displayed reduced GLUT4 
translocation at the cell periphery with concomitant loss of both green 
and red fluorescence signals, indicating that knockdown of Tmod3 
impairs GLUT4 translocation in L6 myoblasts (Figure 3.3.4-A-B: 














Figure 3.3.4 Impairment of AICAR-stimulated GLUT4 translocation 
in L6 myoblasts upon Tmod3 silencing 
(A-B) TIRF-mCherry and TIRF-Myc signals were detected in AICAR 
stimulated scramble L6 myoblasts in the TIRF zone under non-
permeabilized condition. Both TIRF signals significantly decreased in 
Tmod3-KD myoblasts, indicating impairment in GLUT4 translocation.  
Data are presented as the ratio of cell surface TIRF-Myc signals to total 
Epi-mCherry and mean ± SEM of 30 cells in each group from three 
sets of independent experiments. **p<0.01 versus mock + AICAR 

















































































3.3.5 Site of action of Tmod3 in AMPK-stimulated GLUT4 
translocation 
Silencing of Tmod3 did not completely block the GLUT4 translocation 
to the cortical area but reduced the GLUT4 insertion to the plasma 
membrane as indicated by intact red fluorescence and weak green 
fluorescence (Figure 3.3.4-A-B). Latrunculin B inhibits the GLUT4 
vesicle fusion to the plasma membrane but not the trafficking. 
Disruption of cortical actin with Latrunculin B resulted in significant 
accumulation of GLUT4 vesicles in the TIRF zone with significantly 
reduced fusion to the plasma membrane (Figure 3.3.5-A-B: Scramble + 
AICAR [6.15 ± 0.12] versus Scramble + AICAR + Latrunculin B [1.07 ± 
0.25]). These data taken together suggest that Tmod3 is required for 

















Figure 3.3.5 Impairment of AICAR-stimulated GLUT4 translocation 
in L6 myoblasts upon Latrunculin B treatment 
(A-B) TIRF-mCherry and TIRF-Myc signals were detected in AICAR 
stimulated scramble L6 myoblasts in the TIRF zone under non-
permeabilized condition. Both TIRF signals significantly decreased in 
Latrunculin B treated L6 myoblasts, indicating impairment in GLUT4 
vesicle fusion to the plasma membrane.  Data are presented as the 
ratio of cell surface TIRF-Myc signals to total Epi-mCherry and mean ± 
SEM of 30 cells in each group from three sets of independent 
















































































3.4 Role of Tmod3 phosphorylation in activated-AMPK-mediated 
glucose transport and GLUT4 translocation 
3.4.1 Tmod3 phosphorylation promotes activated-AMPK-mediated 
glucose transport 
Previous studies have shown that AICAR stimulates an increase in 
skeletal muscle AMPK activity thereby increasing glucose uptake and 
GLUT4 vesicle translocation from an intracellular location to the plasma 
membranes [187]. Besides Akt2-dependent Tmod3 phosphorylation 
[51], AMPK-dependent Tmod3 phosphorylation could be an important 
step in GLUT4 vesicle translocation. Having demonstrated that 
activated-AMPK phosphorylates Tmod3 at Ser25, it will be interesting 
to determine the effects of Tmod3 phosphorylation at Ser25 on 
activated-AMPK-stimulated glucose transport and GLUT vesicle 
translocation. To determine the role of Ser25 on activated-AMPK-
stimulated glucose transport and GLUT vesicle translocation, shRNA-
resistant Tmod3-WT-RR or Tmod3 variants were generated and 
ectopic lentiviral expressions in endogenous Tmod3 silenced L6 
myoblasts were examined by western blotting as shown in Figure 
3.4.1-A. Upon AMPK activation, the phospho-defective mutant, S25A, 
was found to be inhibitory to activated-AMPK-stimulated glucose 
transport whereas the phospho-mimetic mutant, S25D, significantly 
enhanced the glucose transport capacity. As expected, AMPK inhibitor, 
Compound C treatment led to significant reduction in glucose transport 
in Tmod3-WT and Tmod3 variants (Figure 3.4.1-B). These data taken 
together suggest that Tmod3 phosphorylation at Ser25 is important for 
glucose transport under AMPK activation in L6 myoblasts. 
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Figure 3.4.1 Effects of Tmod3 phosphorylation on activated-
AMPK-mediated glucose transport in L6 myoblasts 
(A) Western blots analysis show the endogenous Tmod3 expression in 
scramble L6 myoblasts and FLAG-tagged Tmod3 variants upon rescue 
in Tmod3-KD L6 myoblasts. Tmod3 expressions were detected by anti-
Tmod3 rabbit antibody and anti-FLAG mouse antibody. Anti-Tubulin 
mouse antibody was used as the loading control. (B) Different variants 
of Tmod3 expressing L6 myoblasts were serum starved for 2 hours, 
treated with or without 2mM AICAR and Compound C for 30 minutes 
for [3H]-2-Deoxyglucose uptake assay. Data are presented as mean ± 
SEM of three independent experiments. **p<0.01 versus Tmod3-WT + 
















3.4.2 Tmod3 phosphorylation promotes activated-AMPK-mediated 
GLUT4 translocation 
To evaluate the effects of Tmod3 variants on activated-AMPK-
stimulated GLUT4 translocation in L6 myoblasts, TIRF-based Myc-
GLUT4-mcherry assay was performed. Data are presented as the ratio 
of cell surface TIRF-Myc signals to total Epi-mCherry which are 
normalized against the Tmo3-WT control group. Upon activation of 
AMPK, Tmod3-WT and phospho-mimetic mutant promoted the GLUT4 
translocation significantly (Figure 3.4.2-A: WT + AICAR [1.79 ± 0.09]; 
S25D + AICAR [2.09 ± 0.08]). On the contrary, phospho-defective 
mutant, S25A, showed significantly lower GLUT4 translocation to the 
plasma membrane in AMPK activated condition (Figure 3.4.2-A: S25A 
+ AICAR [1.03 ± 0.13]). These data indicate that Tmod3 
phosphorylation promotes activated-AMPK-mediated GLUT4 vesicle 

















Figure 3.4.2 Effects of Tmod3 phosphorylation on activated-
AMPK-mediated GLUT4 translocation in L6 myoblasts 
(A-B) Tmod3-WT and phospho-mimetic mutant S25D promotes GLUT4 
vesicle fusion with plasma membrane upon phosphorylation with 
activated-AMPK. Activated-AMPK-induced GLUT4 vesicle fusion was 
examined by TIRF-mCherry and TIRF-Myc signals. Data are presented 
as the ratio of cell surface TIRF-Myc signals to total Epi-mCherry and 
mean ± SEM of 30 cells in each group from three sets of independent 






















































































3.5 Phosphorylation of Tmod3 regulates actin remodeling 
3.5.1 Tmod3 phosphorylation in binding monomeric G-actin and 
nucleation of actin assembly  
All the evidences so far suggest that phosphorylation of Tmod3 
promote activated-AMPK mediated GLUT4 vesicle translocation. 
Previous studies have shown that phosphorylation of Tmod3 regulates 
insulin-induced actin remodeling [51, 120, 188]. Likewise, the activation 
of AMPK induces glucose uptake via actin cytoskeleton remodeling in 
skeletal muscle cells [142] . However, the exact mechanism through 
which phosphorylation of Tmod3 at Ser25 affects GLUT4 translocation 
in terms of actin remodeling is still unclear. One of the characteristic 
features of actin-capping proteins is their ability to bind with monomeric 
G-actin [189]. The ability of Tmod3 to bind with G-actin was tested by 
in vitro actin-cross-linking assay with zero-length cross linker, 
EDC/sulfo-NHS, followed by SDS-PAGE and immuno-blotting with anti-
Tmod3 and anti-actin antibodies (Figure 3.5.1-A). Consistent with 
previous reports, Tmod3-WT and Tmod3-S25D readily formed a 
complex with actin [51, 144, 162, 190]. But, the complex forming 
activity was found to decrease in case of Tmod3-WT and Tmod3-
S25D. By contrast, phospho-defective mutants of Tmod3, S25A and 
S71A, showed increase in Tmod3: Actin complex formation. These 
data suggest that the Tmod3 phosphorylation regulates the binding to 



















Figure 3.5.1 Effects of Tmod3 phosphorylation on binding to 
monomeric G-actin and actin assembly 
(A) Recombinant proteins of Tmod3 variants were prepared and 
visualized by Coomassie Brilliant Blue staining and western blot using 
anti-Tmod3 rabbit antibody. (B) Recombinant proteins of Tmod3 
variants were subjected to in vitro actin cross-linking assay in presence 
or absence of G-actin at equimolar ratio and cross-linked with 
EDC/sulfo-NHS cross-linkers for 45 minutes at room temperature. The 
cross-linking assays were terminated by adding 2X SDS sample buffer 
followed by western blotting with anti-β-actin rabbit antibody and anti-













































Tmod3: actin complex 
IB: anti-actin 
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3.5.2 Tmod3 regulates cortical actin remodeling in vivo 
To study the effects of Tmod3 on activated-AMPK-induced cortical 
actin remodeling in vivo, L6 myoblasts stably expressing Lifeact-
tdTomato were generated. Lifeact, a 17 amino-acid peptide, stains F-
actin structures without interfering actin dynamics in vitro and in vivo 
[191]. Upon AMPK activation, increased F-actin remodeling was 
observed as shown by increased Lifeact-tdTomato fluorescence under 
TIRFM. On contrary, silencing of Tmod3 led to reduced F-actin 
remodeling even after AMPK activation (Figure 3.5.2-B-C) suggesting 
that Tmod3 is required for activated-AMPK induced F-actin remodeling 



























Figure 3.5.2 Effects of Tmod3 on actin remodeling in vivo 
(A) L6 myoblasts stably expressing Lifeact-tdTomato were observed 
under TIRF microscopy. (B) Time-lapse images of actin remodeling in 
L6 myoblasts stably expressing Lifeact-tdTomato under different 
treatment conditions. (C) Area under curve (AUC) in Lifeact-td-Tomato 
fluorescence intensity as a percentage of control group.  **p<0.01 
versus Tmod3-Scr + AICAR treated group. Scale bar: 10μm. 
Lifeact-tdTomato 













































































3.5.3 Phosphorylation of Tmod3 regulates cortical actin 
remodeling in vivo 
To investigate whether activated-AMPK-induced Tmod3 
phosphorylation could affect the actin remodeling in vivo, L6 myoblasts 
stably co-expressing Lifeact-tdTomato and Tmod3-WT or Tmod3 
variants were subjected to AICAR treatment. As compared to basal 
condition, AMPK activation induced cortical actin remodeling as shown 
by increased Lifeact-tdTomato fluorescence under TIRF in WT and 
S25D. Meanwhile, S25A mutant reduced the activated-AMPK-induced 
cortical actin remodeling (Figure 3.5.3-A-B). Together, these data 
suggest that phosphorylation of Tmod3 at Ser25 is important in 
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Figure 3.5.3 Effects of Tmod3 phosphorylation on actin 
remodeling in vivo 
(A) Time-lapse images of actin remodeling in L6 myoblasts stably co-
expressing Lifeact-tdTomato and Tmod3 variants under AICAR-
stimulated condition. (B) Area under curve (AUC) in Lifeact-td-Tomato 
fluorescence intensity as a percentage of control group. **p<0.01 




















































































3.6 Identification of cognate Tmod3 binding Tropomyosin in 
regulating actin capping 
Within the N-terminal domain, Tmod3 has α-helix-1 and α-helix-3 which 
are necessary for interaction with tropomyosin and α-helix-2 which is 
important for G-actin binding and tropomyosin dependent actin capping 
[147, 162, 190]. The binding affinity of Tropomodulin to actin filament 
increases in presence of tropomyosin [192]. Under insulin-stimulated 
condition Tmod3 has been shown to interact with Tm5NM1, the shorter 
form of γTm, but not with other isoforms of tropomyosin in adipocytes 
[51]. Consistent with the previous reports, L6 myoblasts were found to 
express the tropomyosin isoforms Tm1, Tm2, Tm3, Tm4 and Tm5NM1 
(Figure 3.6.1-A) [193]. To identify the cognate Tmod3 interacting 
partner in L6 myoblasts, L6 myoblasts stably expressing FLAG-Tmod3-
WT and Tmod3 variants were treated with or without AICAR and 
subjected to immunoprecipitation using anti-FLAG M2 affinity gel and 
immunoblotted using antibodies against different tropomyosin isoforms 
and anti-FLAG antibody. In L6 myoblasts, Tmod3 was detected to 
interact with Tm2, Tm3 and Tm5NM1 but not with Tm1 and Tm4. The 
lack of interaction between Tmod3 and Tm4 could be either due to the 
low expression of Tm4 expression or low sensitivity of the Tm4 
antibody. In line with the previous reports, Tmod3-L29G/L134D 
(Tmod3-LL) showed significant decrease in binding to Tm5NM1 [51], 
even under AMPK activation.   Moreover, Tmod3: Tropomyosin 
interaction was not affected by the activated-AMPK-induced Tmod3 
phosphorylation (Figure 3.6.1-B). Collectively, these data indicate that 
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Tmod3 interacts with Tm2, Tm3 and Tm5NM1 independent of 
activated-AMPK-induced phosphorylation of Tmod3. In case of Tmod3 
and Tm4 interaction, use of more specific antibody could provide better 

































Figure 3.6.1 Effects of Tmod3 phosphorylation on its binding to 
Tropomyosins 
(A) Expression of different tropomyosin isoforms in L6 myoblasts. (B) 
L6 myoblasts expressing different FLAG-Tmod3 variants were serum 
starved for 2 hours and treated with or without 2mM AICAR for 30 
minutes. Anti-FLAG M2 affinity gel was used for immuno-precipitation 
followed by immuno-blotting with anti-Tm5NM1, anti-Tm2 and 3, anti-

























    Tm3 ← 


































CHAPTER IV DISCUSSION 
4.1 DISCUSSION 
It has been well established that insulin-stimulated glucose transport 
into insulin sensitive tissues like skeletal muscle and adipose tissues 
involves GLUT4 translocation from the intracellular pool to the plasma 
membrane. Previous studies have reported that cortical actin 
remodeling plays indispensable role to link and merge the two lipid 
bilayers between GLUT4 storage vesicles (GSVs) and plasma 
membrane, in co-ordination with the membrane fusion machineries and 
their regulators, like Sec-1/Munc18 proteins, SNARE proteins and 
small GTPases, leading to cell surface exposure of GLUT4 proteins 
and facilitating the glucose transport [118, 120, 124, 139, 188, 194-
196]. 
Recent discovery of Tmod3 as a novel Akt2 substrate has 
provided a molecular mechanism involved in insulin-stimulated GSVs 
fusion with plasma membrane and glucose transport in adipocyte [51]. 
In the muscles, glucose transport occurs via two major pathways, 
insulin dependent and insulin independent signaling pathways. In 
insulin independent pathway, contraction of the skeletal muscles 
stimulates glucose transport through GLUT4 translocation. AMPK is 
activated during exercise or energy deprived condition and promotes 
glucose transport in insulin independent manner [52, 197]. However, 
little has been elucidated regarding mechanisms involved in GLUT4 
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vesicle translocation and glucose transport other than the insulin 
signaling pathway.     
The specificity of targeting distinct GLUT4 vesicle pools by 
AMPK signaling may be conferred by Tmod3. The presence of AMPK 
consensus phosphorylation motif sequence implies that Tmod3 could 
be predominantly an AMPK substrate. Experimental data presented 
from both in-vitro and in vivo studies in this thesis confirm that Tmod3 
is phosphorylated by AMPK-α2 upon activation by AICAR and 2-DG. 
This is further supported by the co-expression of constitutively active 
(CA) or kinase in-active (DN) form of AMPK-α2 with Tmod3-WT in 
which Tmod3 is phosphorylated only in presence of AMPK-α2-CA.  
In addition, over-expression of Tmod3-WT and its variants in 
presence and absence of AMPK-α2-CA and the auto-radiography 
experiments have confirmed that Ser25 in mouse Tmod3 as a distinct 
AMPK phosphorylation site.  Although mass spectrometry analysis 
showed that both Ser25 and Ser27 could be putative AMPK 
phosphorylation sites, biochemical analysis and auto-radiography have 
further verified that Ser25 is indeed the AMPK phosphorylation site in 
Tmod3. The AMPK consensus phosphorylation motif [LLGKLS*ESEL, 
Ser25] is present in both Tmod2 and Tmod3 but not in Tmod1 and 
Tmod4. So, the role of Ser25 phosphorylation in Tmod2 regulated 
pathways in neurons could be interesting to investigate.  
In this study, silencing of Tmod3 in L6 myoblasts has no 
influence on AMPK signaling as AICAR-stimulated AMPK activation 
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remained intact, suggesting that Tmod3 is downstream target for 
AMPK phosphorylation. shRNA silencing of Tmod3 in L6 myoblasts 
inhibited the differentiation process (data not shown), indicating that 
Tmod3 might play a role in myoblast differentiation. This is supported 
by previous studies in which deletion of Tmod3 has been reported to 
cause impairment in erythroid terminal differentiation in fetal liver [152].
 Differentiated myotubes represent the skeletal muscle 
structurally and functionally. Since the Tmod3 silencing inhibited the 
differentiation of myoblasts, it is necessary to investigate the effects of 
differentiation on insulin and AMPK-activated glucose uptake. Upon 
insulin and AMPK activation, significant increase in glucose uptake was 
observed with no difference between the myoblasts and the myotubes. 
The measurement of insulin and AMPK-activated GLUT4 translocation 
to the plasma membrane under confocal and TIRF microscopy using 
myotubes has some technical difficulties as the myotubes overlap with 
one other and the microscopic field doesn’t cover the full length of the 
myotubes under study, making the measurement of the GLUT4 
translocation practically impossible.  
Actin cytoskeleton has been shown to be involved in the signal 
transduction, particularly signaling to insulin-stimulated GLUT4 
translocation. The actin cytoskeleton remodeling is important for 
insulin-induced GLUT4 translocation in L6 myotubes [124, 135, 198] 
and gastrocnemius muscle of mouse. The small Rho family GTPase 
Rac1 has been shown to play important role in this aspect [122, 124, 
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135, 198-200]. It has been shown that exercise in mice and humans 
activates Rac1 in muscles and chemical inhibition or silencing of Rac1 
in muscle leads to partial impairment in contraction-induced glucose 
uptake in mouse muscle indicating the role of cytoskeletal components 
in contraction-induced glucose uptake in muscle [201, 202]. As such, 
Tmod3, which nucleates actin polymerization by binding to actin 
monomers and by capping filaments at pointed end [162], may regulate 
activated-AMPK-induced GLUT4 translocation through actin 
remodeling.  
In consistent with the previous studies, despite the rapid GLUT4 
recycling in L6 myoblasts than in adipocytes [203-207], relatively low 
levels of GLUT4 fused with plasma membrane in the basal state, which 
could be due to a very rapid rate of GLUT4 endocytosis [200]. Upon 
AMPK activation enhanced plasma membrane GLUT4 level was 
observed suggesting the inhibition of GLUT4 endocytosis. In this study, 
there was no significant difference between Tmod3-KD and control, 
and phospho-defective mutant and control L6 myoblasts in the basal 
level of both GLUT4 vesicle translocation and glucose uptake. 
However, rescue of Tmod3-KD L6 myoblasts with phospho-mimetic 
Tmod3 mutant in Tmod3-KD L6 myoblasts rescued the defect in 
activated-AMPK-dependent actin remodeling, along with potentiation in 
activated-AMPK-induced GLUT4 translocation and glucose uptake, as 
shown by TIRFM and [3H]-2-Deoxyglucose uptake assays. 
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Moreover, phospho-mimetic Tmod3 mutant did not show any 
significant increase in GLUT4 translocation or glucose uptake when 
compared with  Tmod3-WT myoblasts, suggesting that phosphorylation 
of Tmod3 alone is not sufficient to regulate the entire activated-AMPK-
induced GLUT4 vesicle translocation and exocytosis. Silencing of 
Tmod3 did not completely block the GLUT4 translocation to the cortical 
area but reduced the GLUT4 insertion to the plasma membrane which 
indicates that Tmod3 is required for GLUT4 vesicle fusion with the 
plasma membrane but not required for trafficking to the cortical area.  
Structurally, Tmod3 contains N-terminal domain with three 
functional α-helices and caps the pointed ends of actin filaments [208-
210]. α-helix-1 and α-helix-3  bind to tropomyosin [208, 209] and α-
helix-2 caps pointed ends of actin filament in a tropomyosin-dependent 
manner [161, 209] forming a co-polymer along the length of actin 
filament [157]. There are about 40 tropomyosins and tropomodulins 
bind to specific types of tropomyosin [158] linking the phosphorylation 
of Tmod3 with the formation of specific type of actin filament. The type 
of tropomyosin dimer regulates the nature of its interactions with actin 
binding proteins and myosin motors, thereby determines the functional 
capacity of the filament [158-160]. In L6 myoblasts, five isoforms of 
tropomyosin, namely Tm1, Tm2, Tm3, Tm4 and Tm5NM1/2, are 
primarily expressed [193]. In the pull-down experiments, Tmod3 was 
detected to interact with Tm2, Tm3 and Tm5NM1 but not with Tm1 and 
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Tm4 which could be due to low expression of Tm1 and Tm4 in L6 
myoblast and low sensitivity of the Tm4 antibody. 
Since both the α-helix-1 and α-helix-3 of Tmod3 are necessary 
for the interaction with tropomyosin, Tmod3 mutant harboring both 
L29G in the α-helix-1 and L134D in the α-helix-3 was generated. The 
L29D and L134D mutations are equivalent to L27E and I131D 
mutations in Tmod1 [211]. Tmod3 with L29G/L134D (Tmod3-LL) has 
been shown to completely lose its binding to Tm5NM1 in adipocytes. In 
line with the previous reports, Tmod3-LL showed significant decrease 
in binding to Tm5NM1 [51], even under AMPK activation suggesting 
that Tmod3 interacts with Tm2, Tm3 and Tm5NM1 independent of 
activated-AMPK-induced phosphorylation of Tmod3 and hence, the 
tmod3-tropomyosin interaction is not required for activated-AMPK-










4.2 SIGNIFICANCE OF CURRENT STUDY 
Muscle contraction and activated-AMPK-induced glucose uptake 
remains intact in case of insulin-resistance. Therefore, characterization 
of insulin-independent signaling pathways leading to GLUT4 vesicle 
translocation and glucose uptake is a crucial process in identifying 
novel anti-diabetic drug targets bypassing the insulin-resistance. The 
investigations detailed in this thesis primarily highlight the significance 
of cortical actin remodeling as crucial molecular machinery involved in 
activated-AMPK-induced GLUT4 vesicle fusion with the plasma 
membrane. The identification of Tmod3 as a novel AMPK substrate 
provides a molecular mechanism regulating activated-AMPK-induced 
actin remodeling. 
The study to identify the downstream effectors of AMPK 
signaling pathway is of therapeutic value as novel AMPK substrate 
could be a potential drug target in order to treat metabolic disorders 
such as type 2 diabetes. The work presented in this thesis supports the 
targeting of Tmod3 for enhancing glucose uptake in muscle cells in 
type 2 diabetic patients. The beneficial effects of commonly prescribed 
anti-diabetic drug, metformin, can be primarily attributed to its inhibition 
of hepatic gluconeogensis [82, 212]. Additional activation of AMPK and 
its substrates at peripheral muscle tissue may provide further beneficial 




4.3 FUTURE WORK 
The studies presented in this thesis are primarily based on biochemical 
and cell biology techniques. The data presented were obtained from L6 
myoblasts as the myoblasts could undergo differentiation after 
silencing Tmod3. L6 myoblasts do not completely represent skeletal 
muscle in vivo structurally and functionally. Nevertheless, the data 
presented indicate that the cell line is of the use to investigate certain 
aspects of glucose transport and GLUT4 translocation in skeletal 
muscle. However, to fully understand the glucose transport and GLUT4 
translocation and their regulation in response to AMPK activation in 
skeletal muscle it is important to perform the studies in vivo.  
Previous studies have reported that besides Tmod1, targeted deletion 
of Tmod3 in mice leads to embryonic lethality at E14.5-E18.5 with 
anemia which is mainly due to defects in erythroid terminal 
differentiation in the fetal liver [145, 150]. More recently, it has been 
reported that Tmod3-null mice embryos have impaired F-actin 
polymerization and megakaryocyte cytoplasmic morphogenesis with 
defects in pro-platelet formation [151].  Considering the effects of 
Tmod3 knockout on the developmental stages, future studies with a 
skeletal muscle restricted Tmod3 deletion in adult mice will be more 
appropriate to evaluate the precise role of Tmod3 in glucose transport 
and GLUT4 translocation at tissue specific level.  
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Tmod3 has been shown to be phosphorylated at Ser71 under 
insulin stimulation in adipocytes [51]. In this thesis, Ser25 has been 
shown to be phosphorylated by activated-AMPK. However, it is still not 
clear how the phosphorylation of Ser25 and Ser71 affects each other. 
In future, it will be interesting to investigate the convergence of insulin-
signaling and AMPK-signaling pathway taking Tmod3 under 
consideration as a focal point. Moreover, insulin-induced and activated-
AMPK-induced GLUT4 vesicle trafficking in L6 cells and adipocytes 
has been reported to maintain enhanced cell surface GLUT4 levels in 
the steady state mainly by inhibiting endocytosis [200, 204, 206, 213]. 
It will be of great interest to explore the role of Tmod3 in regulation of 












4.4 CONCLUSION     
This study reports the identification of Tmod3 as a novel AMPK 
substrate. The phosphorylated Tmod3 promotes membrane and 
cortical actin remodeling independent of tropomyosin, thereby 
facilitating activated-AMPK-mediated GLUT4 fusion with plasma 
membrane and glucose transport in L6 myoblasts. Hence, this study 
highlights the role and mechanism of activated-AMPK-mediated Tmod3 




















Figure 4 Schematic diagram for Tmod3 as an effector between 
activated-AMPK and GLUT4 fusion with the plasma membrane 
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